Page last updated: 2024-12-05

lactulose

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Lactulose is a synthetic disaccharide composed of galactose and fructose. It is not digested or absorbed in the small intestine, but is fermented by bacteria in the colon. This fermentation produces short-chain fatty acids, which have several beneficial effects on the digestive system. Lactulose is used clinically as a laxative for the treatment of constipation and hepatic encephalopathy. The compound is studied for its potential benefits in managing other conditions, such as irritable bowel syndrome and inflammatory bowel disease.'

Lactulose: A synthetic disaccharide used in the treatment of constipation and hepatic encephalopathy. It has also been used in the diagnosis of gastrointestinal disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p887) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

lactulose : A synthetic galactosylfructose disaccharide used in the treatment of constipation and hepatic encephalopathy. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID11333
CHEMBL ID296306
CHEBI ID6359
SCHEMBL ID18912
MeSH IDM0012186
PubMed CID11024312
SCHEMBL ID229408
MeSH IDM0012186

Synonyms (130)

Synonym
lactulosum
4-o-beta-d-galactopyranosyl-beta-d-fructofuranose
lactulosa
DIVK1C_000064
KBIO1_000064
SPECTRUM_000857
IDI1_000064
SPECTRUM5_000908
laxilose
einecs 225-027-7
brn 0093773
portalac
lactulosa [spanish]
constulose
4-o-beta-d-galattopiranosil-d-fruttofuranosio [italian]
enulose
heptalac
laevolac
d-fructose, 4-o-beta-d-galactopyranosyl-
d-lactulose
brn 6278818
lattulosio [italian]
chronulac
cephulac
bifiteral
constilac
beta-d-fructofuranose, 4-o-beta-d-galactopyranosyl-
isolactose
lactulosum [latin]
lactulosum [inn-latin]
4-beta-d-galactosido-(1,4)-d-fructose
fructofuranose, 4-o-beta-d-galactopyranosyl-, d-
lactulosa [inn-spanish]
cholac
generlac
acilac
C07064
4-o-beta-d-galactopyranosyl-d-fructofuranose
DB00581
lactulose (jp17/usp/inn)
D00352
chronulac (tn)
NCGC00094707-01
NCGC00142624-01
4-o-beta-d-galactopyranosyl-d-fructose
KBIO2_003905
KBIO2_001337
KBIO3_001436
KBIO2_006473
KBIOGR_001303
KBIOSS_001337
SPECTRUM2_001159
SPECTRUM3_000478
NINDS_000064
SPBIO_001117
SPECTRUM4_000962
SPECTRUM1500363
BSPBIO_002216
NCGC00142624-02
HMS2094G15
CHEMBL296306
lactulose jp17
4-galactosyl fructose
nsc-757082
chebi:6359 ,
(2s,3r,4s,5r,6r)-2-[(2r,3s,4s,5r)-4,5-dihydroxy-2,5-bis(hydroxymethyl)oxolan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
HMS500D06
HMS1920J03
NCGC00142624-03
58166-24-8
2-[(3s,4s,2r,5r)-2,5-bis(hydroxymethyl)-4,5-dihydroxyoxolan-3-yloxy](2s,4s,3r, 5r,6r)-6-(hydroxymethyl)-2h-3,4,5,6-tetrahydropyran-3,4,5-triol
nsc757082
pharmakon1600-01500363
cas-4618-18-2
dtxcid3025833
dtxsid5045833 ,
tox21_111318
CCG-39552
nsc 757082
actilax
lactulose [usan:usp:inn:ban:jan]
9u7d5qh5ae ,
unii-9u7d5qh5ae
lattulosio
5-17-07-00214 (beilstein handbook reference)
kristalose
4-o-beta-d-galattopiranosil-d-fruttofuranosio
bdbm50377984
w9t
9XH2P2N8EP ,
.alpha.-d-fructofuranose, 4-o-.beta.-d-galactopyranosyl-
.alpha.-lactulose
58166-25-9
SCHEMBL18912
NCGC00142624-05
tox21_111318_1
alpha-lactulose
alpha-d-fructofuranose, 4-o-beta-d-galactopyranosyl-
unii-9xh2p2n8ep
AKOS024283994
AB00052029_02
(2s,3r,4s,5r,6r)-2-{[(2r,3s,4s,5r)-4,5-dihydroxy-2,5-bis(hydroxymethyl)oxolan-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
sr-05000002084
SR-05000002084-4
SR-05000002084-1
delta-lactulose
4-o-b-d-galactopyranosyl-d-fructofuranose
4-o-beta-delta-galactopyranosyl-delta-fructofuranose
4-o-beta-delta-galactopyranosyl-delta-fructose
Q422689
(2s,3r,4s,5r,6r)-2-(((2r,3s,4s,5r)-4,5-dihydroxy-2,5-bis(hydroxymethyl)tetrahydrofuran-3-yl)oxy)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol
EN300-19791535
lactulose solution
beta-d-galactopyranosyl-(1->4)-d-fructose
lactulosa (inn-spanish)
lactulose (usan:usp:inn:ban:jan)
a06ad11
lactulosum (inn-latin)
lactulosum (latin)
lactulose solution usp, 10 g/15 ml
SMP1_000174
duphalac
4618-18-2
lactulose
cephulac (tn)
SCHEMBL229408
4-o-b-d-galactopyranosyl-d-fructose
4-o--d-galactopyranosyl-d-fructofuranose;laevolac; lactulose; cholac; enulose; liforos
(2s,3r,4s,5r,6r)-2-(((2r,3s,4s)-4,5-dihydroxy-2,5-bis(hydroxymethyl)tetrahydrofuran-3-yl)oxy)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol
AKOS040732203

Research Excerpts

Toxicity

Oral lactulose solution is effective and safe for puerperal consipation. PEG can lead to more rapid HE resolution during the first 24 hours.

ExcerptReferenceRelevance
"2,2,2-Trifluoroethanol (TFE) is the toxic metabolite of the anesthetic agent fluroxene."( Mechanism of toxicity of 2,2,2-trifluoroethanol in rats.
Fraser, JM; Kaminsky, LS; Silkworth, JB, 1986
)
0.27
" Both laxatives proved to be safe to use."( Safety and efficacy of a bulk laxative containing senna versus lactulose in the treatment of chronic constipation in geriatric patients.
Kinnunen, O; Koistinen, P; Salokannel, J; Winblad, I, 1993
)
0.29
"Legume lectins can have toxic effects when consumed without adequate cooking, occasionally leading to an acute gastroenteritis."( Sucrose co-administration reduces the toxic effect of lectin on gut permeability and intestinal bacterial colonization.
Dokladny, K; Lin, HC; Moseley, PL; Patel, YR; Ramadass, B, 2010
)
0.36
"Our aim was to test the hypothesis that sucrose may reduce toxic effects of legume lectins by protecting barrier function, bacterial overgrowth and bacterial translocation."( Sucrose co-administration reduces the toxic effect of lectin on gut permeability and intestinal bacterial colonization.
Dokladny, K; Lin, HC; Moseley, PL; Patel, YR; Ramadass, B, 2010
)
0.36
"5 grams of the following (random order): Tm, rice (as reference atoxic protein) and Amygluten (as reference toxic protein) dispersed in a gluten-free pudding."( Search for atoxic cereals: a single blind, cross-over study on the safety of a single dose of Triticum monococcum, in patients with celiac disease.
Di Toro, N; Lanzarotto, F; Lanzini, A; Not, T; Petroboni, B; Pogna, N; Ricci, C; Villanacci, V; Zanini, B, 2013
)
0.39
" Adverse gastrointestinal events were 8 for Tm, Vs 11 for rice (p = 0."( Search for atoxic cereals: a single blind, cross-over study on the safety of a single dose of Triticum monococcum, in patients with celiac disease.
Di Toro, N; Lanzarotto, F; Lanzini, A; Not, T; Petroboni, B; Pogna, N; Ricci, C; Villanacci, V; Zanini, B, 2013
)
0.39
"No definite conclusion can be drawn on the safety of Tm, based on no change in urinary L/R because even Amygluten, a toxic wheat protein, did not cause a significant change in urinary L/R indicating low sensitivity of this methodology in studies on acute toxicity."( Search for atoxic cereals: a single blind, cross-over study on the safety of a single dose of Triticum monococcum, in patients with celiac disease.
Di Toro, N; Lanzarotto, F; Lanzini, A; Not, T; Petroboni, B; Pogna, N; Ricci, C; Villanacci, V; Zanini, B, 2013
)
0.39
" Its adverse effects of dehydration and serum electrolyte imbalances are widely known."( Lactulose-associated lithium toxicity: a case series.
Bregman, A; Fritz, K; Xiong, GL, 2014
)
0.4
" The adverse reactions and recurrence of constipation after treatment were analyzed."( [Efficacy and safety of lactulose on the treatment of puerperal constipation].
Chang, Q; Deng, Q; Meng, S; Pan, Y; Wang, L, 2015
)
0.42
"Oral lactulose solution is effective and safe for puerperal consipation."( [Efficacy and safety of lactulose on the treatment of puerperal constipation].
Chang, Q; Deng, Q; Meng, S; Pan, Y; Wang, L, 2015
)
0.42
" The secondary endpoints included the change from baseline of SBMs at Week 2, percentage of patients experiencing SBM within 24 and/or 48 h of the initial dose, stool consistency, and constipation severity, and adverse events were also evaluated."( Efficacy and safety of a crystalline lactulose preparation (SK-1202) in Japanese patients with chronic constipation: a randomized, double-blind, placebo-controlled, dose-finding study.
Fukudo, S; Iwai, H; Kasugai, K; Kuboyama, N; Yoshikawa, A, 2019
)
0.51
" There were no significant differences in the incidence of adverse drug reactions (ADRs) between the placebo and SK-1202 groups."( Efficacy and safety of a crystalline lactulose preparation (SK-1202) in Japanese patients with chronic constipation: a randomized, double-blind, placebo-controlled, dose-finding study.
Fukudo, S; Iwai, H; Kasugai, K; Kuboyama, N; Yoshikawa, A, 2019
)
0.51
"This study will provide a high-quality integration of current evidence of lactulose for treating IBS on several aspects including global IBS symptoms, abdominal pain, defecation urgency, stool frequency, stool consistency, quality of life, and adverse events."( Efficacy and safety of lactulose for the treatment of irritable bowel syndrome.
Chen, HB; Su, XY, 2019
)
0.51
" The percentages of patients with any specific adverse event did not differ significantly between groups."( Efficacy and Safety of Ornithine Phenylacetate for Treating Overt Hepatic Encephalopathy in a Randomized Trial.
Bajaj, JS; Bhamidimarri, KR; Bukofzer, S; Potthoff, A; Pyrsopoulos, N; Rahimi, RS; Safadi, R; Thabut, D, 2021
)
0.62
" However, OP appears to be safe and should undergo further testing for treatment of hyperammonemia in hospitalized patients receiving treatment for the underlying precipitant of acute or overt HE."( Efficacy and Safety of Ornithine Phenylacetate for Treating Overt Hepatic Encephalopathy in a Randomized Trial.
Bajaj, JS; Bhamidimarri, KR; Bukofzer, S; Potthoff, A; Pyrsopoulos, N; Rahimi, RS; Safadi, R; Thabut, D, 2021
)
0.62
" Both groups were given a 3-week course of treatment, and were observed for any adverse drug reactions."( A comparison of the safety and efficacy of polyethylene glycol 4000 and lactulose for the treatment of constipation in pregnant women: a randomized controlled clinical study.
Li, H; Xue, Y; Zhang, P, 2020
)
0.56
" There was no significant difference in the incidence of adverse events (RR=0."( Comparative Effectiveness and Safety of Polyethylene Glycol Electrolyte Solution Versus Lactulose for Treatment of Hepatic Encephalopathy: A Systematic Review and Meta-analysis.
Chen, Q; Huang, J; Li, M; Shui, D; Zhang, Z; Zhou, X, 2022
)
0.72
" Compared with lactulose, PEG can lead to more rapid HE resolution during the first 24 hours and shorten the length of stay without increasing the rate of adverse effects."( Comparative Effectiveness and Safety of Polyethylene Glycol Electrolyte Solution Versus Lactulose for Treatment of Hepatic Encephalopathy: A Systematic Review and Meta-analysis.
Chen, Q; Huang, J; Li, M; Shui, D; Zhang, Z; Zhou, X, 2022
)
0.72
"To identify predictors of severe adverse events (≥grade 3) in patients with advanced hepatocellular carcinoma treated with lenvatinib."( Leaky Gut and Severe Adverse Events in Advanced Hepatocellular Carcinoma Treated With Lenvatinib.
Akahane, T; Enomoto, M; Fujimoto, Y; Fujinaga, Y; Inoue, T; Kaji, K; Kawaratani, H; Kitagawa, K; Mitoro, A; Moriya, K; Murata, K; Namisaki, T; Nishimura, N; Sawada, Y; Takaya, H; Takeda, S; Tsuji, Y; Yoshiji, H, 2022
)
0.72
"Of 41 patients, 25 and 16 were stratified into the severe and non-severe adverse events groups, respectively."( Leaky Gut and Severe Adverse Events in Advanced Hepatocellular Carcinoma Treated With Lenvatinib.
Akahane, T; Enomoto, M; Fujimoto, Y; Fujinaga, Y; Inoue, T; Kaji, K; Kawaratani, H; Kitagawa, K; Mitoro, A; Moriya, K; Murata, K; Namisaki, T; Nishimura, N; Sawada, Y; Takaya, H; Takeda, S; Tsuji, Y; Yoshiji, H, 2022
)
0.72
"Severe adverse event incidence rates were higher in patients with advanced hepatocellular carcinoma related to alcoholic liver disease and nonalcoholic fatty-liver disease than in those with advanced hepatocellular carcinoma of other etiologies (p=0."( Leaky Gut and Severe Adverse Events in Advanced Hepatocellular Carcinoma Treated With Lenvatinib.
Akahane, T; Enomoto, M; Fujimoto, Y; Fujinaga, Y; Inoue, T; Kaji, K; Kawaratani, H; Kitagawa, K; Mitoro, A; Moriya, K; Murata, K; Namisaki, T; Nishimura, N; Sawada, Y; Takaya, H; Takeda, S; Tsuji, Y; Yoshiji, H, 2022
)
0.72
"Serum zonulin levels predict severe adverse events in patients with advanced hepatocellular carcinoma treated with lenvatinib."( Leaky Gut and Severe Adverse Events in Advanced Hepatocellular Carcinoma Treated With Lenvatinib.
Akahane, T; Enomoto, M; Fujimoto, Y; Fujinaga, Y; Inoue, T; Kaji, K; Kawaratani, H; Kitagawa, K; Mitoro, A; Moriya, K; Murata, K; Namisaki, T; Nishimura, N; Sawada, Y; Takaya, H; Takeda, S; Tsuji, Y; Yoshiji, H, 2022
)
0.72

Compound-Compound Interactions

PEG combined with lactulose may be a better choice for bowel preparation before colonoscopy compared with PEG alone. Mirabilite combined with Lactulose can be considered as an easy intervention to improve postoperative gastrointestinal mobility in older intensive care patients.

ExcerptReferenceRelevance
"These findings may suggest that calcium in combination with magnesium and lactulose can reduce body fat mass in middle-aged Japanese women."( Reducing effect of calcium in combination with magnesium and lactulose on body fat mass in middle-aged Japanese women.
Abe, F; Asano, Y; Kudou, H; Ochi, H; Seki, N; Uenishi, K, 2013
)
0.39
" This study investigates the impact on gut microbiome when a commonly used antibiotic, azithromycin is administered, as well as uncovers the benefits induced when it is used in combination with lactulose, a prebiotic known to enhance the proliferation of commensal microbes."( Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose.
Antoniades, A; Kamilari, E; Nikolaou, E; Savkov, D; Sergeev, A; Shammas, C; Tomazou, M; Vogazianos, P; Zakharova, I, 2020
)
0.56
"16S rRNA gene sequencing analysis of stool samples obtained from 87 children treated with azithromycin in combination with or without lactulose have been determined."( Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose.
Antoniades, A; Kamilari, E; Nikolaou, E; Savkov, D; Sergeev, A; Shammas, C; Tomazou, M; Vogazianos, P; Zakharova, I, 2020
)
0.56
"The main aim of the present study was to assess the efficacy of polyethylene glycol electrolyte (PEG) solution combined with lactulose in bowel preparation to find a new method for colonoscopy preparation to improve the quality of colonoscopy in patients with long interval preparation-to-colonoscopy (P-C)."( The advantage of polyethylene glycol electrolyte solution combined with lactulose in patients with long interval preparation-to-colonoscopy.
Jianping, N; Man, M; Tao, L; Xueping, L; Yuanchao, H, 2020
)
0.56
"PEG solution combined with lactulose can improve the quality of colonoscopy in patients with long interval P-C to allow the patients to select more flexible colonoscopy time."( The advantage of polyethylene glycol electrolyte solution combined with lactulose in patients with long interval preparation-to-colonoscopy.
Jianping, N; Man, M; Tao, L; Xueping, L; Yuanchao, H, 2020
)
0.56
"To evaluate the feasibility and efficacy of Mirabilite combined with Lactulose in older patients after abdominal surgery."( External use of Mirabilite combined with Lactulose improves postoperative gastrointestinal mobility among older patients undergoing abdominal surgery.
Cai, S; Latour, JM; Li, J; Lv, M; Pan, W; Zhang, X; Zhang, Y; Zhong, M, 2021
)
0.62
"This study demonstrated that external use of Mirabilite combined with Lactulose can be considered as an easy intervention to improve postoperative gastrointestinal mobility in older intensive care patients who suffer from postoperative gastrointestinal tract dysfunction after surgery."( External use of Mirabilite combined with Lactulose improves postoperative gastrointestinal mobility among older patients undergoing abdominal surgery.
Cai, S; Latour, JM; Li, J; Lv, M; Pan, W; Zhang, X; Zhang, Y; Zhong, M, 2021
)
0.62
" In our study, the effects of several polysaccharides such as alginate, κ-carrageenan, locust bean gum, gellan gum, xanthan gum and their combination with various prebiotic components (resistant starch, lactulose, lactosucrose) on encapsulation of probiotic Lactobacillus casei 01 strain were studied."( Effects of various polysaccharides (alginate, carrageenan, gums, chitosan) and their combination with prebiotic saccharides (resistant starch, lactosucrose, lactulose) on the encapsulation of probiotic bacteria Lactobacillus casei 01 strain.
Antal, O; Bujna, E; Gupta, VK; Juhász, R; Kun, S; Ladányi, M; Nguyen, QD; Sudheer, S; Szécsi, A; Ta, LP, 2021
)
0.62
"To explore the effect of probiotics combined with prebiotics on clinical hypothyroidism during pregnancy combined with small intestinal bacterial overgrowth."( Efficacy evaluation of probiotics combined with prebiotics in patients with clinical hypothyroidism complicated with small intestinal bacterial overgrowth during the second trimester of pregnancy.
Ban, Y; Cai, Y; Hao, Y; Li, J; Ouyang, Q; Sun, Z; Wang, M; Wang, W; Wu, B; Xu, Y; Zhang, M, 2022
)
0.72
" (2) SIBO-positive patients in the clinical hypothyroidism group during pregnancy (n=112) were treated with probiotics combined with prebiotics based on conventional levothyroxine sodium tablets treatment."( Efficacy evaluation of probiotics combined with prebiotics in patients with clinical hypothyroidism complicated with small intestinal bacterial overgrowth during the second trimester of pregnancy.
Ban, Y; Cai, Y; Hao, Y; Li, J; Ouyang, Q; Sun, Z; Wang, M; Wang, W; Wu, B; Xu, Y; Zhang, M, 2022
)
0.72
" (4) After 21 days of probiotics combined with prebiotics, the incidence of pure methane positivity in the methane-hydrogen breath test in the G21 group was significantly reduced, and the average abundance of hydrogen and methane at each time point in the G21 group was lower than that in the G0 group."( Efficacy evaluation of probiotics combined with prebiotics in patients with clinical hypothyroidism complicated with small intestinal bacterial overgrowth during the second trimester of pregnancy.
Ban, Y; Cai, Y; Hao, Y; Li, J; Ouyang, Q; Sun, Z; Wang, M; Wang, W; Wu, B; Xu, Y; Zhang, M, 2022
)
0.72
"Probiotics combined with prebiotics are effective in the treatment of pregnant patients with clinical hypothyroidism complicated with SIBO, providing a new idea to treat pregnant patients with clinical hypothyroidism complicated with SIBO."( Efficacy evaluation of probiotics combined with prebiotics in patients with clinical hypothyroidism complicated with small intestinal bacterial overgrowth during the second trimester of pregnancy.
Ban, Y; Cai, Y; Hao, Y; Li, J; Ouyang, Q; Sun, Z; Wang, M; Wang, W; Wu, B; Xu, Y; Zhang, M, 2022
)
0.72
" However, its cryoprotective effect in combination with lecithin on the main representatives of probiotics has not been tested yet."( Lactulose in combination with soybean lecithin has a cryoprotective effect on probiotic taxa of bifidobacteria and Lactobacillaceae.
Bunešová, VN; Killer, J; Modráčková, N; Pechar, R; Šplíchal, I; Vlková, E, 2023
)
0.91
" This study aimed to compare the efficacy and adverse reactions of Polyethylene Glycol (PEG) combined with lactulose with that of PEG alone in bowel preparation before colonoscopy."( Polyethylene glycol combined with lactulose has better efficacy than polyethylene glycol alone in bowel preparation before colonoscopy: A meta-analysis.
Chen, Y; Lamm, S; Li, L; Tang, C; Zhang, X; Zhu, W, 2023
)
0.91
" The meta-analysis showed that PEG combined with lactulose had a better efficacy (OR = 3."( Polyethylene glycol combined with lactulose has better efficacy than polyethylene glycol alone in bowel preparation before colonoscopy: A meta-analysis.
Chen, Y; Lamm, S; Li, L; Tang, C; Zhang, X; Zhu, W, 2023
)
0.91
"PEG combined with lactulose may be a better choice for bowel preparation before colonoscopy compared with PEG alone."( Polyethylene glycol combined with lactulose has better efficacy than polyethylene glycol alone in bowel preparation before colonoscopy: A meta-analysis.
Chen, Y; Lamm, S; Li, L; Tang, C; Zhang, X; Zhu, W, 2023
)
0.91
"This study aimed to investigate the clinical effect of probiotics combined with lactulose for minimal hepatic encephalopathy (MHE) treatment."( Clinical study of probiotics combined with lactulose for minimal hepatic encephalopathy treatment.
Li, F; Shi, J, 2023
)
0.91

Bioavailability

Lactulose is a poorly absorbed synthetic disaccharide frequently used in the treatment of portasystemic encephalopathy. Other sugars thought to be poorly absorbed in the small intestine (xylitol, lactobionate, arabinose) stimulated Ca absorption to an identical extent as lactulose.

ExcerptReferenceRelevance
" The new methodology may, therefore, be used for fast bioavailability screening of virtual libraries having millions of molecules."( Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.
Ertl, P; Rohde, B; Selzer, P, 2000
)
0.31
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" The disaccharide lactulose (galactosyl-beta-1,4-fructose) was poorly absorbed from rat small intestine in vitro and human mouth in vivo."( Absorption of lactulose from mammalian gastrointestinal tract.
Evered, DF; Sadoogh-Abasian, F, 1979
)
0.26
" Oral corticosteroids have been used for patients who seem to be resistant to gluten withdrawal but preparations with low systemic bioavailability might be preferable."( A pilot study of fluticasone propionate in untreated coeliac disease.
al Mardini, H; Gillespie, S; Laker, M; Mitchison, HC; Record, CO; Zaitoun, A, 1991
)
0.28
"To determine the effects of poorly absorbed solute on intestinal absorption, the urinary recovery of ingested lactulose, L-rhamnose, D-xylose, and 3-O-methyl-D-glucose was measured after simultaneous ingestion of various 'loads' of mannitol given in iso-osmolar solution."( The effect of poorly absorbed solute on intestinal absorption.
Catt, SD; Creamer, B; Heduan, E; Jenkins, AP; Menzies, IS; Segal, MB, 1990
)
0.28
"To determine whether the acidifying effect of malabsorbed carbohydrate on fecal pH differed between methane-excreting and nonexcreting individuals, we administered the poorly absorbed disaccharide lactulose to five CH4 excretors and six CH4 nonexcretors."( Nonabsorbed carbohydrate: effect on fecal pH in methane-excreting and nonexcreting individuals.
Flick, JA; Perman, JA, 1989
)
0.28
" To test this hypothesis, we assessed intestinal permeability with the nonmetabolizable, poorly absorbed disaccharide lactulose, which is efficiently excluded by the normal intestinal mucosa."( Increased intestinal permeability associated with infection in burn patients.
Demling, RH; O'Dwyer, ST; Smith, RJ; Wilmore, DW; Ziegler, TR, 1988
)
0.27
"Fructo-oligosaccharides are naturally occurring sweet substances that are poorly absorbed and have the potential to be clinically useful nonnutritive sweeteners."( Gaseous response to ingestion of a poorly absorbed fructo-oligosaccharide sweetener.
Levitt, MD; Stone-Dorshow, T, 1987
)
0.27
"Lactulose is a poorly absorbed synthetic disaccharide frequently used in the treatment of portasystemic encephalopathy."( Marked deterioration in glycemic control with change in brand of lactulose syrup.
Filippini, SA; Kirkman, MS; Zimmerman, DR, 1995
)
0.29
"We have previously shown that small oral doses of poorly absorbed solute can significantly reduce absorption of test sugars in normal volunteers."( The effect of ingested lactulose on absorption of L-rhamnose, D-xylose, and 3-O-methyl-D-glucose in subjects with ileostomies.
Creamer, B; Jenkins, AP; Menzies, IS; Nukajam, WS, 1994
)
0.29
" Expressed as percent per segment, D-glucose absorption ranged from 29-50%, and the lactulose absorption rate was 4-5%."( Effect of absorption of D-glucose and water on paracellular transport in rat duodenum-jejunum.
Gisolfi, C; O'Rourke, M; Schedl, H; Shi, X, 1995
)
0.29
" Other sugars thought to be poorly absorbed in the small intestine (xylitol, lactobionate, arabinose, raffinose, pyroglutamate, sorbitol, gluconate and raftilose) stimulated Ca absorption to an identical extent as lactulose."( Intestinal calcium absorption in rats is stimulated by dietary lactulose and other resistant sugars.
Antille, S; Binacua, C; Brommage, R; Carrié, AL, 1993
)
0.29
"Lactulose and lactitol, the synthetic compounds of lactose, are poorly absorbed from the small intestine, and both are almost exclusively metabolized by the bacterial flora of the colon."( [Lactulose and its derivatives--treatment of hepatic encephalopathy and other possible indications for its use].
Fehér, J; Prónai, L, 1993
)
0.29
" Repercussions on calcium bioavailability in powder and in-bottle-sterilized liquid infant formulas were studied."( Does processing of a powder or in-bottle-sterilized liquid infant formula affect calcium bioavailability?
López-Fandiño, R; Sarriá, B; Vaquero, MP, 2001
)
0.31
"Determination of the consequences of a high level of lactuloselysine in milk on the bioavailability of skim milk nutrients and the kinetics of their appearance in the portal blood and of their urinary and faecal excretions and extrapolation to lower heat treatments and to man, using the pig model."( Nutritional and metabolic consequences of the early Maillard reaction of heat treated milk in the pig. Significance for man.
Calmes, R; Finot, PA; Rérat, A; Vaissade, P, 2002
)
0.31
" The transport of water was monitored, and the absorption rate of the probes was calculated by their disappearance from the perfusate."( Water absorption enhances the uptake of mannitol and decreases Cr-EDTA/mannitol permeability ratios in cat small intestine in situ.
Bijlsma, PB; Fihn, BM; Groot, JA; Jodal, M; Sjöqvist, A; Taminiau, JA, 2002
)
0.31
" Bioavailability was calculated as F=AUC by gavage/AUC by injection, where AUC is the area under the curve of plasma probe concentration vs."( Intestinal passive absorption of water-soluble compounds by sparrows: effect of molecular size and luminal nutrients.
Caviedes-Vidal, E; Chediack, JG; Fasulo, V; Karasov, WH; Yamin, LJ, 2003
)
0.32
"Rifaximin is a rifamycin analogue with a broad spectrum of activity similar to that of rifampin; however, because it is poorly absorbed in the gastrointestinal tract, the focus of its development has been on intestinal infections and diseases."( Rifaximin: a nonabsorbed oral antibiotic.
Baker, DE, 2005
)
0.33
" The objective of this research was to study intestinal absorptive function and bioavailability of rifampin and isoniazid in TB patients."( Intestinal permeability and malabsorption of rifampin and isoniazid in active pulmonary tuberculosis.
Barroso, EC; Bushen, OY; Façanha, MC; Guerrant, RL; Lima, AA; Monteiro, HS; Peloquin, CA; Pinheiro, VG; Ramos, LM, 2006
)
0.33
" When experiments aimed at increasing the oral bioavailability of hydrophilic compounds are performed, timing of fasting should be extremely accurate."( Fasting increases tobramycin oral absorption in mice.
De Leo, L; Decorti, G; Di Toro, N; Malusà, N; Not, T; Ventura, A, 2010
)
0.36
" Aim of this study was to test the efficacy of liquid levodopa with higher bioavailability in patients with SIBO."( Liquid melevodopa versus standard levodopa in patients with Parkinson disease and small intestinal bacterial overgrowth.
Bentivoglio, AR; Bove, F; Fasano, A; Fortuna, S; Gabrielli, M; Gasbarrini, A; Marconi, S; Ragazzoni, E; Tortora, A; Zocco, MA,
)
0.13
" This case suggested that a breath test is effective for the identification of SIBO and that the administration of a poorly absorbed antibiotic should be considered in SIBO-positive HE patients taking lactulose."( Small Intestinal Bacterial Overgrowth Diagnosed by a Breath Test and Improved by Rifaximin in a Patient with Hepatic Encephalopathy and Alcoholic Liver Cirrhosis.
Kamimura, H; Kamimura, K; Sakamaki, A; Takamura, M; Terai, S; Yamazaki, F; Yokoyama, J; Yokoyama, K, 2020
)
0.56

Dosage Studied

Lactulose (Laevolac Cristalli, CAS 4618-18-2) was administered to 10 cirrhotic patients for 30 days at the dosage of 60 g/d. LactulOSE also accelerated movement through the rest of the colon so that at 24 hours after dosing the geometric center of the isotope bolus was distal to that seen during the control study.

ExcerptRelevanceReference
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
" Part I of this paper is a review of the actions, clinical use, side effects, and dosage and administration of these new drugs."( Some aspects of medical management of gastrointestinal disease. I.
Badley, BW, 1975
)
0.25
" The dosage was 30 ml daily taken at bedtime; it was reduced to 15 ml if the initial dosage produced two or more bowel movements daily."( Lactulose syrup assessed in a double-blind study of elderly constipated patients.
Sanders, JF, 1978
)
0.26
" Lactulose also accelerated movement through the rest of the colon so that at 24 hours after dosing the geometric center of the isotope bolus was distal to that seen during the control study (6."( Scintigraphic demonstration of lactulose-induced accelerated proximal colon transit.
Barrow, L; Davies, MC; Melia, CD; Spiller, RC; Steed, KP; Watts, PJ; Wilson, CG, 1992
)
0.28
"Crystalline lactulose (Laevolac Cristalli, CAS 4618-18-2), a pure form of the disaccharide widely employed in the therapy of complications of liver cirrhosis, was administered, after a pharmacological wash-out of 10 days and following a randomized design, to 10 cirrhotic patients for 30 days at the dosage of 60 g/d, while another 10 subjects with similar characteristics received no treatment."( Crystalline lactulose in the therapy of hepatic cirrhosis. Evaluation of clinical and immunological parameters. Preliminary results.
Altamura, M; Altomare, E; Cirelli, F; De Vincentiis, A; Palasciano, G; Vendemiale, G, 1992
)
0.28
" This rise was not affected by concomitant dosage of metronidazole."( The contribution of the large intestine to blood acetate in man.
Cummings, JH; Elia, M; Pomare, EW; Scheppach, W, 1991
)
0.28
"An intestinal permeability test analyzing the differential urinary elimination of lactulose and mannitol orally ingested at the same dosage was carried out first in fasting condition, then combined with specific food ingestion, in 17 children with clinical symptoms of irritable bowel syndrome (IBS)."( Modifications of intestinal permeability during food provocation procedures in pediatric irritable bowel syndrome.
Barau, E; Dupont, C, 1990
)
0.28
" The dose-response effect of mannitol on the absorption of L-rhamnose was approximately exponential; doses of 5, 10, and 20 g mannitol reduced the average urinary excretion of L-rhamnose by 34."( The effect of poorly absorbed solute on intestinal absorption.
Catt, SD; Creamer, B; Heduan, E; Jenkins, AP; Menzies, IS; Segal, MB, 1990
)
0.28
" For evaluating the better dosage of lactulose in gastroenterological routine diagnostic we designed a prospective study."( [The H2-lactulose breath test in the diagnosis of intestinal transit time].
Malfertheiner, P; Pieramico, O; Wilberg, S, 1990
)
0.28
" Ten out of the 23 patients were continuously treated with lactulose at a dosage of 18 g/day for eight weeks."( Short term effect of lactulose therapy in patients with chronic renal failure.
Miura, M; Nomoto, Y; Sakai, H, 1989
)
0.28
" This paper describes dose-response relationships between dietary lactulose and cholesterol in either serum or liver."( Increased concentrations of liver cholesterol in rats fed lactulose.
Beynen, AC, 1989
)
0.28
" lactulose in chronic recurrent portal-systemic encephalopathy (PSE), 25 cirrhotic patients with a history of repeated episodes of hepatic encephalopathy who required chronic administration of lactulose were included in a controlled cross-over clinical trial in which patients received, at random, lactitol (at an initial dosage of 10 g/6 h) or lactulose (15 ml/6 h, 66% w/v, containing 10 g of lactulose) during a 3 month period and then crossed-over to the alternative treatment for the following 3 months."( Lactitol vs. lactulose in the treatment of chronic recurrent portal-systemic encephalopathy.
Heredia, D; Orteu, N; Rodés, J; Terés, J, 1988
)
0.27
" In all cases the excessive flatulence occurred independently of sugar dosage whereas the development of diarrhoea was dose-related."( Lactitol versus lactulose in the treatment of chronic hepatic encephalopathy. A double-blind, randomised, cross-over study.
Hawley, KE; Morgan, MY; Stambuk, D, 1987
)
0.27
" using a relative dosage is a suitable test for children, but under the age of 1 year it is less useful because of the high percentage of non-responders."( A comparative study of the mouth to caecum transit time in children and adults using a weight adapted lactulose dose.
Bouquet, J; Sinaasappel, M; Vreugdenhil, G, 1986
)
0.27
" Dose-response experiments revealed that normal subjects could tolerate 120-220 mmol of mannitol, 73-146 mmol of lactulose, or 80 mmol of raffinose before fecal output of water exceeded 400 ml in 48 h or before test carbohydrate appeared in the stool."( Conservation of mannitol, lactulose, and raffinose by the human colon.
Saunders, DR; Wiggins, HS, 1981
)
0.26
" NSAID dose-response curves produced using the two indices of damage showed that intestinal permeability is as sensitive and reproducible as ulceration, although changes could not be detected before visible ulceration occurred."( Assessment of intestinal permeability changes induced by nonsteroidal anti-inflammatory drugs in the rat.
Ford, J; Houston, JB; Martin, SW, 1995
)
0.29
" The patients were treated for 15 consecutive days with rifaximin, an antibiotic which is not absorbed by the intestinal wall, at a dosage of 1200 mg/day in association with sufficient lactulose to induce 2 or 3 evacuations per day."( Rifaximin in the treatment of chronic hepatic encephalopathy.
Ferrieri, A; Massimetti, A; Puxeddu, A; Quartini, M, 1995
)
0.29
" A dose-response study of RPS, 5, 10, 25, 50, 75 and 100 g was performed."( Intestinal transport and fermentation of resistant starch evaluated by the hydrogen breath test.
Gudmand-Høyer, E; Olesen, M; Rumessen, JJ, 1994
)
0.29
" The dose-response study with RPS showed that even 5 g of RPS resulted in a measurable increase in end-expiratory H2, and increasing doses from 5 g to 100 g resulted in a seemingly exponential increase in H2 production."( Intestinal transport and fermentation of resistant starch evaluated by the hydrogen breath test.
Gudmand-Høyer, E; Olesen, M; Rumessen, JJ, 1994
)
0.29
" Urine was collected for 5 h, test sugar content being subsequently measured by thin-layer chromatography for the dosing sugars."( Intestinal permeability and function in patients infected with human immunodeficiency virus. A comparison with coeliac disease.
Johnson, MA; Lee, CA; Lim, SG; Menzies, IS; Pounder, RE, 1993
)
0.29
"3% wt/wt) and were then dosed orally with a human fecal suspension."( The effect of lactulose on DNA damage induced by DMH in the colon of human flora-associated rats.
Bearne, CA; Fischer, R; Pool-Zobel, BL; Rowland, IR, 1996
)
0.29
" The aim of this study was to determine whether a low dosage of lactulose is able to discriminate between normal and increased permeability."( The sensitivity of the lactulose/rhamnose gut permeability test.
Brouns, F; Brummer, RJ; Deutz, NE; Geerling, BJ; van Nieuwenhoven, MA, 1999
)
0.3
"The transitory laxative threshold of a partially digestible disaccharide, trehalose, and an undigestible disaccharide, lactulose, was estimated by the dose-response relation between the test substance and the prevalence of diarrhea in 20 healthy female subjects."( Transitory laxative threshold of trehalose and lactulose in healthy women.
Okazaki, M; Oku, T, 1998
)
0.3
" In conclusion, in postmenopausal women a 9-day consumption of lactulose increases calcium absorption in a dose-response way."( Lactulose stimulates calcium absorption in postmenopausal women.
Muijs, T; Schaafsma, G; Van den Heuvel, EG; Van Dokkum, W, 1999
)
0.3
" In both cases no dose-response relation was observed."( Variations in colonic H2 and CO2 production as a cause of inadequate diagnosis of carbohydrate maldigestion in breath tests.
de Bruijn, S; Koetse, HA; Pal, J; Pasterkamp, S; Stellaard, F; Vonk, RJ, 2000
)
0.31
" The oral route is optimized by dosing every hour until stool evacuation appears."( Hepatic Encephalopathy.
Blei, AT; Córdoba, J, 2001
)
0.31
" 5-ASA was first detected in plasma after 3 h, which is the reported colon arrival time for indigestible solids, after dosing to fasting dogs."( Studies on lactulose formulations for colon-specific drug delivery.
Fukui, M; Katsuma, M; Kawai, H; Masuda, Y; Takemura, S; Watanabe, S, 2002
)
0.31
"5 g/kg were supplied orally for 14 days in Gln group, and the same dosage of placebo were given for 14 days in B group."( Effects of enteral supplementation with glutamine granules on intestinal mucosal barrier function in severe burned patients.
Peng, X; Wang, P; Wang, S; Yan, H; You, Z, 2004
)
0.32
" Participants received lactulose (Duphalac) or polyethylene glycol-4000 (Forlax) powders for the first week at a fixed dosage at night (20 g/day); in the second week, patients were given the option to vary the dose according to efficacy and tolerance (10-30 g/day); for the last 2 weeks, treatment was administered at a fixed dosage based on the results of the second week (10-30 g/day)."( Prospective, randomized, parallel-group trial to evaluate the effects of lactulose and polyethylene glycol-4000 on colonic flora in chronic idiopathic constipation.
Andrieux, C; Bouhnik, Y; Dyard, F; Flourié, B; Guillemot, F; Michel, C; Neut, C; Raskine, L; Riottot, M, 2004
)
0.32
"LGG, as dosed in this study, was not an effective adjunct to lactulose in treating constipation in children."( Ineffectiveness of Lactobacillus GG as an adjunct to lactulose for the treatment of constipation in children: a double-blind, placebo-controlled randomized trial.
Banaszkiewicz, A; Szajewska, H, 2005
)
0.33
"In order to understand the consequences of persistent enteral feeding in patients with carbohydrate malabsorption, we fed piglets lactulose in sufficient dosage to produce osmotic diarrhea or inulin, using a conventional dose, to determine if this prebiotic can modulate the effects of lactulose."( Lactulose feeding lowers cecal densities of clostridia in piglets.
Blauwiekel, R; Buddington, RK; Bunn, JY; Kien, CL; Williams, CH,
)
0.13
"Medical records were reviewed, and 27 children with chronic constipation satisfying the following criteria were enrolled: (i) on stable maintenance medication for ≥ 3 months; (ii) no dosage modification or drug change between the two periods compared; (iii) no clinical events during the investigation that could affect intake or the clinical outcomes; (iv) good compliance regarding inclusion in the diaries of the frequency of bowel movements, the consistency of stools, and the amount of fluid intake."( Effect of fluid intake on the outcome of constipation in children: PEG 4000 versus lactulose.
Bae, SH; Lee, R; Son, JS, 2010
)
0.36
" Pigs were dosed by oral gavage with a marker solution containing lactulose (disaccharide) and the monosaccharides l-rhamnose, 3-O-methylglucose, and d-xylose at 2 h and at 4, 8, and 12 d after weaning."( Lactulose as a marker of intestinal barrier function in pigs after weaning.
Gort, G; Perdok, HB; van Kempen, TA; Verstegen, MW; Verstijnen, JJ; Wijtten, PJ, 2011
)
0.37
"We included randomised trials that compared probiotics in any dosage with placebo or no intervention, or with any other treatment in patients with hepatic encephalopathy."( Probiotics for patients with hepatic encephalopathy.
Bakens, A; McGee, RG; Riordan, SM; Webster, AC; Wiley, K, 2011
)
0.37
"Twenty healthy female volunteers each received 600 mg aspirin or placebo in random sequence and were subsequently dosed with 10 g lactulose and 5 g mannitol, their urine collected every half hour for 6h."( The effect of aspirin and smoking on urinary excretion profiles of lactulose and mannitol in young women: toward a dynamic, aspirin augmented, test of gut mucosal permeability.
Hurst, RD; Kruger, MC; Lentle, RG; Sequeira, IR, 2012
)
0.38
" Hence, variation in sampling period and in method of dosage are likely to influence the result and it is preferable to examine the patterns of absorption of component sugars separately with due regard to the method of dosage."( The effect of aspirin and smoking on urinary excretion profiles of lactulose and mannitol in young women: toward a dynamic, aspirin augmented, test of gut mucosal permeability.
Hurst, RD; Kruger, MC; Lentle, RG; Sequeira, IR, 2012
)
0.38
" The results show that a binge dosing regimen of METH to the rat increased plasma and brain ammonia concentrations that were paralleled by evidence of hepatotoxicity."( Peripheral ammonia as a mediator of methamphetamine neurotoxicity.
Halpin, LE; Yamamoto, BK, 2012
)
0.38
"The correct dosage of lactulose for the prevention of oral morphine-induced constipation is 60 ml/d."( [Clinical observation of prophylactic lactulose for prevention of oral morphine-induced constipation].
Gu, XQ; Jiao, XD; Lan, HF; Lou, C; Qian, JX; Wang, MM; Wang, Z; Xiao, M; Yuan, LY, 2012
)
0.38
" The forms of these curves did not change significantly following dosing with aspirin."( Differential trafficking of saccharidic probes following aspirin in clinical tests of intestinal permeability in young healthy women.
Hurst, RD; Kruger, MC; Lentle, RG; Sequeira, IR, 2014
)
0.4
"01) were observed 6 h after oral dosage of lactulose."( Assessment of gastrointestinal permeability by lactulose test in sheep after repeated indomethacin treatment.
Ahmed, S; Bani, P; Bertoni, G; Minuti, A; Piccioli-Cappelli, F; Trevisi, E, 2013
)
0.39
" Half-hourly lactulose excretions were generally increased after dosage with aspirin whilst those of mannitol were unchanged as was the temporal pattern and period of lowest between subject standard error for both sugars."( Standardising the lactulose mannitol test of gut permeability to minimise error and promote comparability.
Hurst, RD; Kruger, MC; Lentle, RG; Sequeira, IR, 2014
)
0.4
"5 kg of wheat flour was orally dosed at 0 and 12 h of the experimental period to ACID, while the basal diet (grass hay, ad libitum) was restored to control."( Experimental acute rumen acidosis in sheep: consequences on clinical, rumen, and gastrointestinal permeability conditions and blood chemistry.
Ahmed, S; Bani, P; Bertoni, G; Jahan, N; Minuti, A; Piccioli-Cappelli, F; Trevisi, E, 2014
)
0.4
" The effects of administration of 600 mg aspirin alone, 500 mg ascorbic acid alone and simultaneous dosage of both agents were compared in a cross-over study in 28 healthy female volunteers."( Ascorbic Acid may Exacerbate Aspirin-Induced Increase in Intestinal Permeability.
Hurst, RD; Kruger, MC; Lentle, RG; Sequeira, IR, 2015
)
0.42
"Proton pump inhibitors have no significant influence on lactulose breath tests, regardless of the dosage and time of administration."( [Influence of proton pump inhibitors on intestinal fermentative profile: a case-control study].
Argüello, M; Dima, G; Lasa, J; Peralta, D; Senderovky, M; Soifer, L, 2014
)
0.4
"We included randomised clinical trials that compared probiotics in any dosage with placebo or no intervention, or with any other treatment in people with hepatic encephalopathy."( Probiotics for people with hepatic encephalopathy.
Dalal, R; McGee, RG; Riordan, SM; Webster, AC, 2017
)
0.46
"Ninety six (96) patients of hepatic encephalopathy were randomly assigned to receive either lactulose and rifaximin in standard dosage or lactulose only and their response to therapy was monitored using standard assessment tools."( A Randomized Controlled Trial Comparing the Efficacy of a Combination of Rifaximin and Lactulose with Lactulose only in the Treatment of Overt Hepatic Encephalopathy.
Bandyopadhyay, D; Banik, S; Bhattacherjee, S; Datta, S; Hasan, S; Saha, S, 2018
)
0.48
"Findings will provide timely information on the safety, efficacy, and optimal dosing of t-PA to treat moderate/severe COVID-19-induced ARDS, which can be rapidly adapted to a phase III trial (NCT04357730; FDA IND 149634)."(
Abbasi, S; Abd El-Wahab, A; Abdallah, M; Abebe, G; Aca-Aca, G; Adama, S; Adefegha, SA; Adidigue-Ndiome, R; Adiseshaiah, P; Adrario, E; Aghajanian, C; Agnese, W; Ahmad, A; Ahmad, I; Ahmed, MFE; Akcay, OF; Akinmoladun, AC; Akutagawa, T; Alakavuklar, MA; Álava-Rabasa, S; Albaladejo-Florín, MJ; Alexandra, AJE; Alfawares, R; Alferiev, IS; Alghamdi, HS; Ali, I; Allard, B; Allen, JD; Almada, E; Alobaid, A; Alonso, GL; Alqahtani, YS; Alqarawi, W; Alsaleh, H; Alyami, BA; Amaral, BPD; Amaro, JT; Amin, SAW; Amodio, E; Amoo, ZA; Andia Biraro, I; Angiolella, L; Anheyer, D; Anlay, DZ; Annex, BH; Antonio-Aguirre, B; Apple, S; Arbuznikov, AV; Arinsoy, T; Armstrong, DK; Ash, S; Aslam, M; Asrie, F; Astur, DC; Atzrodt, J; Au, DW; Aucoin, M; Auerbach, EJ; Azarian, S; Ba, D; Bai, Z; Baisch, PRM; Balkissou, AD; Baltzopoulos, V; Banaszewski, M; Banerjee, S; Bao, Y; Baradwan, A; Barandika, JF; Barger, PM; Barion, MRL; Barrett, CD; Basudan, AM; Baur, LE; Baz-Rodríguez, SA; Beamer, P; Beaulant, A; Becker, DF; Beckers, C; Bedel, J; Bedlack, R; Bermúdez de Castro, JM; Berry, JD; Berthier, C; Bhattacharya, D; Biadgo, B; Bianco, G; Bianco, M; Bibi, S; Bigliardi, AP; Billheimer, D; Birnie, DH; Biswas, K; Blair, HC; Bognetti, P; Bolan, PJ; Bolla, JR; Bolze, A; Bonnaillie, P; Borlimi, R; Bórquez, J; Bottari, NB; Boulleys-Nana, JR; Brighetti, G; Brodeur, GM; Budnyak, T; Budnyk, S; Bukirwa, VD; Bulman, DM; Burm, R; Busman-Sahay, K; Butcher, TW; Cai, C; Cai, H; Cai, L; Cairati, M; Calvano, CD; Camacho-Ordóñez, A; Camela, E; Cameron, T; Campbell, BS; Cansian, RL; Cao, Y; Caporale, AS; Carciofi, AC; Cardozo, V; Carè, J; Carlos, AF; Carozza, R; Carroll, CJW; Carsetti, A; Carubelli, V; Casarotta, E; Casas, M; Caselli, G; Castillo-Lora, J; Cataldi, TRI; Cavalcante, ELB; Cavaleiro, A; Cayci, Z; Cebrián-Tarancón, C; Cedrone, E; Cella, D; Cereda, C; Ceretti, A; Ceroni, M; Cha, YH; Chai, X; Chang, EF; Chang, TS; Chanteux, H; Chao, M; Chaplin, BP; Chaturvedi, S; Chaturvedi, V; Chaudhary, DK; Chen, A; Chen, C; Chen, HY; Chen, J; Chen, JJ; Chen, K; Chen, L; Chen, Q; Chen, R; Chen, SY; Chen, TY; Chen, WM; Chen, X; Chen, Y; Cheng, G; Cheng, GJ; Cheng, J; Cheng, YH; Cheon, HG; Chew, KW; Chhoker, S; Chiu, WN; Choi, ES; Choi, MJ; Choi, SD; Chokshi, S; Chorny, M; Chu, KI; Chu, WJ; Church, AL; Cirrincione, A; Clamp, AR; Cleff, MB; Cohen, M; Coleman, RL; Collins, SL; Colombo, N; Conduit, N; Cong, WL; Connelly, MA; Connor, J; Cooley, K; Correa Ramos Leal, I; Cose, S; Costantino, C; Cottrell, M; Cui, L; Cundall, J; Cutaia, C; Cutler, CW; Cuypers, ML; da Silva Júnior, FMR; Dahal, RH; Damiani, E; Damtie, D; Dan-Li, W; Dang, Z; Dasa, SSK; Davin, A; Davis, DR; de Andrade, CM; de Jong, PL; de Oliveira, D; de Paula Dorigam, JC; Dean, A; Deepa, M; Delatour, C; Dell'Aiera, S; Delley, MF; den Boer, RB; Deng, L; Deng, Q; Depner, RM; Derdau, V; Derici, U; DeSantis, AJ; Desmarini, D; Diffo-Sonkoue, L; Divizia, M; Djenabou, A; Djordjevic, JT; Dobrovolskaia, MA; Domizi, R; Donati, A; Dong, Y; Dos Santos, M; Dos Santos, MP; Douglas, RG; Duarte, PF; Dullaart, RPF; Duscha, BD; Edwards, LA; Edwards, TE; Eichenwald, EC; El-Baba, TJ; Elashiry, M; Elashiry, MM; Elashry, SH; Elliott, A; Elsayed, R; Emerson, MS; Emmanuel, YO; Emory, TH; Endale-Mangamba, LM; Enten, GA; Estefanía-Fernández, K; Estes, JD; Estrada-Mena, FJ; Evans, S; Ezra, L; Faria de, RO; Farraj, AK; Favre, C; Feng, B; Feng, J; Feng, L; Feng, W; Feng, X; Feng, Z; Fernandes, CLF; Fernández-Cuadros, ME; Fernie, AR; Ferrari, D; Florindo, PR; Fong, PC; Fontes, EPB; Fontinha, D; Fornari, VJ; Fox, NP; Fu, Q; Fujitaka, Y; Fukuhara, K; Fumeaux, T; Fuqua, C; Fustinoni, S; Gabbanelli, V; Gaikwad, S; Gall, ET; Galli, A; Gancedo, MA; Gandhi, MM; Gao, D; Gao, K; Gao, M; Gao, Q; Gao, X; Gao, Y; Gaponenko, V; Garber, A; Garcia, EM; García-Campos, C; García-Donas, J; García-Pérez, AL; Gasparri, F; Ge, C; Ge, D; Ge, JB; Ge, X; George, I; George, LA; Germani, G; Ghassemi Tabrizi, S; Gibon, Y; Gillent, E; Gillies, RS; Gilmour, MI; Goble, S; Goh, JC; Goiri, F; Goldfinger, LE; Golian, M; Gómez, MA; Gonçalves, J; Góngora-García, OR; Gonul, I; González, MA; Govers, TM; Grant, PC; Gray, EH; Gray, JE; Green, MS; Greenwald, I; Gregory, MJ; Gretzke, D; Griffin-Nolan, RJ; Griffith, DC; Gruppen, EG; Guaita, A; Guan, P; Guan, X; Guerci, P; Guerrero, DT; Guo, M; Guo, P; Guo, R; Guo, X; Gupta, J; Guz, G; Hajizadeh, N; Hamada, H; Haman-Wabi, AB; Han, TT; Hannan, N; Hao, S; Harjola, VP; Harmon, M; Hartmann, MSM; Hartwig, JF; Hasani, M; Hawthorne, WJ; Haykal-Coates, N; Hazari, MS; He, DL; He, P; He, SG; Héau, C; Hebbar Kannur, K; Helvaci, O; Heuberger, DM; Hidalgo, F; Hilty, MP; Hirata, K; Hirsch, A; Hoffman, AM; Hoffmann, JF; Holloway, RW; Holmes, RK; Hong, S; Hongisto, M; Hopf, NB; Hörlein, R; Hoshino, N; Hou, Y; Hoven, NF; Hsieh, YY; Hsu, CT; Hu, CW; Hu, JH; Hu, MY; Hu, Y; Hu, Z; Huang, C; Huang, D; Huang, DQ; Huang, L; Huang, Q; Huang, R; Huang, S; Huang, SC; Huang, W; Huang, Y; Huffman, KM; Hung, CH; Hung, CT; Huurman, R; Hwang, SM; Hyun, S; Ibrahim, AM; Iddi-Faical, A; Immordino, P; Isla, MI; Jacquemond, V; Jacques, T; Jankowska, E; Jansen, JA; Jäntti, T; Jaque-Fernandez, F; Jarvis, GA; Jatt, LP; Jeon, JW; Jeong, SH; Jhunjhunwala, R; Ji, F; Jia, X; Jia, Y; Jian-Bo, Z; Jiang, GD; Jiang, L; Jiang, W; Jiang, WD; Jiang, Z; Jiménez-Hoyos, CA; Jin, S; Jobling, MG; John, CM; John, T; Johnson, CB; Jones, KI; Jones, WS; Joseph, OO; Ju, C; Judeinstein, P; Junges, A; Junnarkar, M; Jurkko, R; Kaleka, CC; Kamath, AV; Kang, X; Kantsadi, AL; Kapoor, M; Karim, Z; Kashuba, ADM; Kassa, E; Kasztura, M; Kataja, A; Katoh, T; Kaufman, JS; Kaupp, M; Kehinde, O; Kehrenberg, C; Kemper, N; Kerr, CW; Khan, AU; Khan, MF; Khan, ZUH; Khojasteh, SC; Kilburn, S; Kim, CG; Kim, DU; Kim, DY; Kim, HJ; Kim, J; Kim, OH; Kim, YH; King, C; Klein, A; Klingler, L; Knapp, AK; Ko, TK; Kodavanti, UP; Kolla, V; Kong, L; Kong, RY; Kong, X; Kore, S; Kortz, U; Korucu, B; Kovacs, A; Krahnert, I; Kraus, WE; Kuang, SY; Kuehn-Hajder, JE; Kurz, M; Kuśtrowski, P; Kwak, YD; Kyttaris, VC; Laga, SM; Laguerre, A; Laloo, A; Langaro, MC; Langham, MC; Lao, X; Larocca, MC; Lassus, J; Lattimer, TA; Lazar, S; Le, MH; Leal, DB; Leal, M; Leary, A; Ledermann, JA; Lee, JF; Lee, MV; Lee, NH; Leeds, CM; Leeds, JS; Lefrandt, JD; Leicht, AS; Leonard, M; Lev, S; Levy, K; Li, B; Li, C; Li, CM; Li, DH; Li, H; Li, J; Li, L; Li, LJ; Li, N; Li, P; Li, T; Li, X; Li, XH; Li, XQ; Li, XX; Li, Y; Li, Z; Li, ZY; Liao, YF; Lin, CC; Lin, MH; Lin, Y; Ling, Y; Links, TP; Lira-Romero, E; Liu, C; Liu, D; Liu, H; Liu, J; Liu, L; Liu, LP; Liu, M; Liu, T; Liu, W; Liu, X; Liu, XH; Liu, Y; Liuwantara, D; Ljumanovic, N; Lobo, L; Lokhande, K; Lopes, A; Lopes, RMRM; López-Gutiérrez, JC; López-Muñoz, MJ; López-Santamaría, M; Lorenzo, C; Lorusso, D; Losito, I; Lu, C; Lu, H; Lu, HZ; Lu, SH; Lu, SN; Lu, Y; Lu, ZY; Luboga, F; Luo, JJ; Luo, KL; Luo, Y; Lutomski, CA; Lv, W; M Piedade, MF; Ma, J; Ma, JQ; Ma, JX; Ma, N; Ma, P; Ma, S; Maciel, M; Madureira, M; Maganaris, C; Maginn, EJ; Mahnashi, MH; Maierhofer, M; Majetschak, M; Malla, TR; Maloney, L; Mann, DL; Mansuri, A; Marelli, E; Margulis, CJ; Marrella, A; Martin, BL; Martín-Francés, L; Martínez de Pinillos, M; Martínez-Navarro, EM; Martinez-Quintanilla Jimenez, D; Martínez-Velasco, A; Martínez-Villaseñor, L; Martinón-Torres, M; Martins, BA; Massongo, M; Mathew, AP; Mathews, D; Matsui, J; Matsumoto, KI; Mau, T; Maves, RC; Mayclin, SJ; Mayer, JM; Maynard, ND; Mayr, T; Mboowa, MG; McEvoy, MP; McIntyre, RC; McKay, JA; McPhail, MJW; McVeigh, AL; Mebazaa, A; Medici, V; Medina, DN; Mehmood, T; Mei-Li, C; Melku, M; Meloncelli, S; Mendes, GC; Mendoza-Velásquez, C; Mercadante, R; Mercado, MI; Merenda, MEZ; Meunier, J; Mi, SL; Michels, M; Mijatovic, V; Mikhailov, V; Milheiro, SA; Miller, DC; Ming, F; Mitsuishi, M; Miyashita, T; Mo, J; Mo, S; Modesto-Mata, M; Moeller, S; Monte, A; Monteiro, L; Montomoli, J; Moore, EE; Moore, HB; Moore, PK; Mor, MK; Moratalla-López, N; Moratilla Lapeña, L; Moreira, R; Moreno, MA; Mörk, AC; Morton, M; Mosier, JM; Mou, LH; Mougharbel, AS; Muccillo-Baisch, AL; Muñoz-Serrano, AJ; Mustafa, B; Nair, GM; Nakanishi, I; Nakanjako, D; Naraparaju, K; Nawani, N; Neffati, R; Neil, EC; Neilipovitz, D; Neira-Borrajo, I; Nelson, MT; Nery, PB; Nese, M; Nguyen, F; Nguyen, MH; Niazy, AA; Nicolaï, J; Nogueira, F; Norbäck, D; Novaretti, JV; O'Donnell, T; O'Dowd, A; O'Malley, DM; Oaknin, A; Ogata, K; Ohkubo, K; Ojha, M; Olaleye, MT; Olawande, B; Olomo, EJ; Ong, EWY; Ono, A; Onwumere, J; Ortiz Bibriesca, DM; Ou, X; Oza, AM; Ozturk, K; Özütemiz, C; Palacio-Pastrana, C; Palaparthi, A; Palevsky, PM; Pan, K; Pantanetti, S; Papachristou, DJ; Pariani, A; Parikh, CR; Parissis, J; Paroul, N; Parry, S; Patel, N; Patel, SM; Patel, VC; Pawar, S; Pefura-Yone, EW; Peixoto Andrade, BCO; Pelepenko, LE; Peña-Lora, D; Peng, S; Pérez-Moro, OS; Perez-Ortiz, AC; Perry, LM; Peter, CM; Phillips, NJ; Phillips, P; Pia Tek, J; Piner, LW; Pinto, EA; Pinto, SN; Piyachaturawat, P; Poka-Mayap, V; Polledri, E; Poloni, TE; Ponessa, G; Poole, ST; Post, AK; Potter, TM; Pressly, BB; Prouty, MG; Prudêncio, M; Pulkki, K; Pupier, C; Qian, H; Qian, ZP; Qiu, Y; Qu, G; Rahimi, S; Rahman, AU; Ramadan, H; Ramanna, S; Ramirez, I; Randolph, GJ; Rasheed, A; Rault, J; Raviprakash, V; Reale, E; Redpath, C; Rema, V; Remucal, CK; Remy, D; Ren, T; Ribeiro, LB; Riboli, G; Richards, J; Rieger, V; Rieusset, J; Riva, A; Rivabella Maknis, T; Robbins, JL; Robinson, CV; Roche-Campo, F; Rodriguez, R; Rodríguez-de-Cía, J; Rollenhagen, JE; Rosen, EP; Rub, D; Rubin, N; Rubin, NT; Ruurda, JP; Saad, O; Sabell, T; Saber, SE; Sabet, M; Sadek, MM; Saejio, A; Salinas, RM; Saliu, IO; Sande, D; Sang, D; Sangenito, LS; Santos, ALSD; Sarmiento Caldas, MC; Sassaroli, S; Sassi, V; Sato, J; Sauaia, A; Saunders, K; Saunders, PR; Savarino, SJ; Scambia, G; Scanlon, N; Schetinger, MR; Schinkel, AFL; Schladweiler, MC; Schofield, CJ; Schuepbach, RA; Schulz, J; Schwartz, N; Scorcella, C; Seeley, J; Seemann, F; Seinige, D; Sengoku, T; Seravalli, J; Sgromo, B; Shaheen, MY; Shan, L; Shanmugam, S; Shao, H; Sharma, S; Shaw, KJ; Shen, BQ; Shen, CH; Shen, P; Shen, S; Shen, Y; Shen, Z; Shi, J; Shi-Li, L; Shimoda, K; Shoji, Y; Shun, C; Silva, MA; Silva-Cardoso, J; Simas, NK; Simirgiotis, MJ; Sincock, SA; Singh, MP; Sionis, A; Siu, J; Sivieri, EM; Sjerps, MJ; Skoczen, SL; Slabon, A; Slette, IJ; Smith, MD; Smith, S; Smith, TG; Snapp, KS; Snow, SJ; Soares, MCF; Soberman, D; Solares, MD; Soliman, I; Song, J; Sorooshian, A; Sorrell, TC; Spinar, J; Staudt, A; Steinhart, C; Stern, ST; Stevens, DM; Stiers, KM; Stimming, U; Su, YG; Subbian, V; Suga, H; Sukhija-Cohen, A; Suksamrarn, A; Suksen, K; Sun, J; Sun, M; Sun, P; Sun, W; Sun, XF; Sun, Y; Sundell, J; Susan, LF; Sutjarit, N; Swamy, KV; Swisher, EM; Sykes, C; Takahashi, JA; Talmor, DS; Tan, B; Tan, ZK; Tang, L; Tang, S; Tanner, JJ; Tanwar, M; Tarazi, Z; Tarvasmäki, T; Tay, FR; Teketel, A; Temitayo, GI; Thersleff, T; Thiessen Philbrook, H; Thompson, LC; Thongon, N; Tian, B; Tian, F; Tian, Q; Timothy, AT; Tingle, MD; Titze, IR; Tolppanen, H; Tong, W; Toyoda, H; Tronconi, L; Tseng, CH; Tu, H; Tu, YJ; Tung, SY; Turpault, S; Tuynman, JB; Uemoto, AT; Ugurlu, M; Ullah, S; Underwood, RS; Ungell, AL; Usandizaga-Elio, I; Vakonakis, I; van Boxel, GI; van den Beucken, JJJP; van der Boom, T; van Slegtenhorst, MA; Vanni, JR; Vaquera, A; Vasconcellos, RS; Velayos, M; Vena, R; Ventura, G; Verso, MG; Vincent, RP; Vitale, F; Vitali, S; Vlek, SL; Vleugels, MPH; Volkmann, N; Vukelic, M; Wagner Mackenzie, B; Wairagala, P; Waller, SB; Wan, J; Wan, MT; Wan, Y; Wang, CC; Wang, H; Wang, J; Wang, JF; Wang, K; Wang, L; Wang, M; Wang, S; Wang, WM; Wang, X; Wang, Y; Wang, YD; Wang, YF; Wang, Z; Wang, ZG; Warriner, K; Weberpals, JI; Weerachayaphorn, J; Wehrli, FW; Wei, J; Wei, KL; Weinheimer, CJ; Weisbord, SD; Wen, S; Wendel Garcia, PD; Williams, JW; Williams, R; Winkler, C; Wirman, AP; Wong, S; Woods, CM; Wu, B; Wu, C; Wu, F; Wu, P; Wu, S; Wu, Y; Wu, YN; Wu, ZH; Wurtzel, JGT; Xia, L; Xia, Z; Xia, ZZ; Xiao, H; Xie, C; Xin, ZM; Xing, Y; Xing, Z; Xu, S; Xu, SB; Xu, T; Xu, X; Xu, Y; Xue, L; Xun, J; Yaffe, MB; Yalew, A; Yamamoto, S; Yan, D; Yan, H; Yan, S; Yan, X; Yang, AD; Yang, E; Yang, H; Yang, J; Yang, JL; Yang, K; Yang, M; Yang, P; Yang, Q; Yang, S; Yang, W; Yang, X; Yang, Y; Yao, JC; Yao, WL; Yao, Y; Yaqub, TB; Ye, J; Ye, W; Yen, CW; Yeter, HH; Yin, C; Yip, V; Yong-Yi, J; Yu, HJ; Yu, MF; Yu, S; Yu, W; Yu, WW; Yu, X; Yuan, P; Yuan, Q; Yue, XY; Zaia, AA; Zakhary, SY; Zalwango, F; Zamalloa, A; Zamparo, P; Zampini, IC; Zani, JL; Zeitoun, R; Zeng, N; Zenteno, JC; Zepeda-Palacio, C; Zhai, C; Zhang, B; Zhang, G; Zhang, J; Zhang, K; Zhang, Q; Zhang, R; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, B; Zhao, D; Zhao, G; Zhao, H; Zhao, Q; Zhao, R; Zhao, S; Zhao, T; Zhao, X; Zhao, XA; Zhao, Y; Zhao, Z; Zheng, Z; Zhi-Min, G; Zhou, CL; Zhou, HD; Zhou, J; Zhou, W; Zhou, XQ; Zhou, Z; Zhu, C; Zhu, H; Zhu, L; Zhu, Y; Zitzmann, N; Zou, L; Zou, Y, 2022
)
0.72
" Lactulose dosing was not significant for hazard of extubation."( Rate of Successful Extubation in Mechanically Ventilated Patients with Cirrhosis and Hepatic Coma.
Gibbs, JT; Louissaint, J; Tapper, EB, 2022
)
0.72
" These analyses evaluate dosing for prevention of cirrhosis complication-related hospitalizations/mortality and overt hepatic encephalopathy (OHE) treatment."( Dosing of Rifaximin Soluble Solid Dispersion Tablets in Adults With Cirrhosis: 2 Randomized, Placebo-controlled Trials.
Bajaj, JS; Hassanein, TI; Heimanson, Z; Israel, RJ; Pyrsopoulos, NT; Rahimi, RS; Rockey, DC; Sanyal, AJ, 2023
)
0.91
"10 pigs were orally dosed with a solution of lactulose and mannitol mixture."( Correlation of lactulose-to-mannitol ratios in plasma and urine for intestinal permeability assessment in pigs.
Benner, CP; Fuller, TE; Hu, SX, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
laxativeAn agent that produces a soft formed stool, and relaxes and loosens the bowels, typically used over a protracted period, to relieve constipation. Compare with cathartic, which is a substance that accelerates defecation. A substances can be both a laxative and a cathartic.
gastrointestinal drugA drug used for its effects on the gastrointestinal system, e.g. controlling gastric acidity, regulating gastrointestinal motility and water flow, and improving digestion.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
glycosylfructose
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
regulator of G-protein signaling 4Homo sapiens (human)Potency2.11920.531815.435837.6858AID504845
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency6.00700.000214.376460.0339AID720691
GVesicular stomatitis virusPotency37.90830.01238.964839.8107AID1645842
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency33.48890.001024.504861.6448AID743215
Interferon betaHomo sapiens (human)Potency37.90830.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency37.90830.01238.964839.8107AID1645842
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency37.90830.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency37.90830.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (45)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (18)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (22)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (117)

Assay IDTitleYearJournalArticle
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID230098Ratio of percent compound after dosing in cirrhotic patients of spontaneous ascitic fluid infection2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
Studies on intestinal permeability of cirrhotic patients by analysis lactulose and mannitol in urine with HPLC/RID/MS.
AID7591Percent of compound in healthy individuals (Group D)2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
Studies on intestinal permeability of cirrhotic patients by analysis lactulose and mannitol in urine with HPLC/RID/MS.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1850984Displacement of thiazole orange from human ILPR G4 quadruplex DNA at 10 equiv. at pH 7.4 by fluorescent intercalator displacement assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Identification of sugar-containing natural products that interact with i-motif DNA.
AID18847Percent of drug absorbed by human intestine after oral administration2000Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20
Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.
AID1850985Displacement of thiazole orange from human ILPR G4 quadruplex DNA at 100 equiv. at pH 7.4 by fluorescent intercalator displacement assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Identification of sugar-containing natural products that interact with i-motif DNA.
AID1850971Binding affinity to human telomeric IKF1 G4 quadruplex DNA assessed as change in melting temperature at 20 uM at pH 7.4 by FRET assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Identification of sugar-containing natural products that interact with i-motif DNA.
AID230100Ratio of percent compound before dosing in cirrhotic patients of spontaneous ascitic fluid infection2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
Studies on intestinal permeability of cirrhotic patients by analysis lactulose and mannitol in urine with HPLC/RID/MS.
AID1850989Displacement of thiazole orange from human ILPR i-motif DNA at 100 equiv. at pH 5.5 by fluorescent intercalator displacement assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Identification of sugar-containing natural products that interact with i-motif DNA.
AID229574Ratio of lactulose and mannitol in cirrhotic patients of sterile ascitic fluid (Group C)2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
Studies on intestinal permeability of cirrhotic patients by analysis lactulose and mannitol in urine with HPLC/RID/MS.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID7976Percent recovery of 10 ug/mL compound after administration in cirrhotic patients2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
Studies on intestinal permeability of cirrhotic patients by analysis lactulose and mannitol in urine with HPLC/RID/MS.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID7586Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
Studies on intestinal permeability of cirrhotic patients by analysis lactulose and mannitol in urine with HPLC/RID/MS.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1850986Displacement of thiazole orange from human ILPR i-motif DNA at 10 equiv. at pH 7.4 by fluorescent intercalator displacement assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Identification of sugar-containing natural products that interact with i-motif DNA.
AID7587Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
Studies on intestinal permeability of cirrhotic patients by analysis lactulose and mannitol in urine with HPLC/RID/MS.
AID7590Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C)2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
Studies on intestinal permeability of cirrhotic patients by analysis lactulose and mannitol in urine with HPLC/RID/MS.
AID1850973Binding affinity to human telomeric 1ELN i-motif DNA assessed as change in melting temperature at 20 uM at pH 5.5 by FRET assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Identification of sugar-containing natural products that interact with i-motif DNA.
AID1850974Binding affinity to human ILPR G4 quadruplex DNA assessed as change in melting temperature at 20 uM at pH 7.4 by FRET assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Identification of sugar-containing natural products that interact with i-motif DNA.
AID476929Human intestinal absorption in po dosed human2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID1850980Displacement of thiazole orange from human telomeric 1ELN i-motif DNA at 10 equiv. at pH 7.4 by fluorescent intercalator displacement assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Identification of sugar-containing natural products that interact with i-motif DNA.
AID625278FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of no concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID28399Cellular permeability (Pc) (Caco-2 cell monolayer)2001Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12
Experimental and computational screening models for the prediction of intestinal drug absorption.
AID592681Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
QSAR-based permeability model for drug-like compounds.
AID229575Ratio of lactulose and mannitol in healthy individuals (Group D)2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
Studies on intestinal permeability of cirrhotic patients by analysis lactulose and mannitol in urine with HPLC/RID/MS.
AID1850991Displacement of thiazole orange from human 1BNA double stranded DNA at 100 equiv. at pH 7.4 by fluorescent intercalator displacement assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Identification of sugar-containing natural products that interact with i-motif DNA.
AID1850987Displacement of thiazole orange from human ILPR i-motif DNA at 100 equiv. at pH 7.4 by fluorescent intercalator displacement assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Identification of sugar-containing natural products that interact with i-motif DNA.
AID236913Permeability Coefficient in Caco-2 cell culture model2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Exploring the role of different drug transport routes in permeability screening.
AID15120Percent of the drug absorbed after administration to humans was determined1999Journal of medicinal chemistry, May-20, Volume: 42, Issue:10
Molecular hashkeys: a novel method for molecular characterization and its application for predicting important pharmaceutical properties of molecules.
AID7589Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
Studies on intestinal permeability of cirrhotic patients by analysis lactulose and mannitol in urine with HPLC/RID/MS.
AID1850977Binding affinity to human 1BNA double stranded DNA assessed as change in melting temperature at 20 uM at pH 7.4 by FRET assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Identification of sugar-containing natural products that interact with i-motif DNA.
AID567091Drug absorption in human assessed as human intestinal absorption rate2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
AID236916Percentage of mass balance in hexadecane membranes model2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Exploring the role of different drug transport routes in permeability screening.
AID71736Inhibitory concentration against Escherichia coli heat-labile enterotoxin (LT) binding to ganglioside GD1b was determined by ELISA assay1999Journal of medicinal chemistry, May-20, Volume: 42, Issue:10
The role of waters in docking strategies with incremental flexibility for carbohydrate derivatives: heat-labile enterotoxin, a multivalent test case.
AID1850978Displacement of thiazole orange from human telomeric IKF1 G4 quadruplex DNA at 10 equiv. at pH 7.4 by fluorescent intercalator displacement assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Identification of sugar-containing natural products that interact with i-motif DNA.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID231333Ratio of [(apical to basal)/(basal to apical)] (Caco-2 cell monolayer)2001Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12
Experimental and computational screening models for the prediction of intestinal drug absorption.
AID1850990Displacement of thiazole orange from human 1BNA double stranded DNA at 10 equiv. at pH 7.4 by fluorescent intercalator displacement assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Identification of sugar-containing natural products that interact with i-motif DNA.
AID230099Ratio of percent compound before and after dosing in cirrhotic patients of spontaneous ascitic fluid infection2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
Studies on intestinal permeability of cirrhotic patients by analysis lactulose and mannitol in urine with HPLC/RID/MS.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID368571Inhibition of Trypanosoma cruzi trans-Sialidase2009Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3
Discovery of novel inhibitors of Trypanosoma cruzi trans-sialidase from in silico screening.
AID7585Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B)2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
Studies on intestinal permeability of cirrhotic patients by analysis lactulose and mannitol in urine with HPLC/RID/MS.
AID156202Binding to POPC (palmitoyl-oleolyl-phosphatidyl-choline) liposomes using biosensor system2000Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11
SPR biosensor studies of the direct interaction between 27 drugs and a liposome surface: correlation with fraction absorbed in humans.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1850988Displacement of thiazole orange from human ILPR i-motif DNA at 10 equiv. at pH 5.5 by fluorescent intercalator displacement assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Identification of sugar-containing natural products that interact with i-motif DNA.
AID1850972Binding affinity to human telomeric 1ELN i-motif DNA assessed as change in melting temperature at 20 uM at pH 7.4 by FRET assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Identification of sugar-containing natural products that interact with i-motif DNA.
AID236914Permeability Coefficient in hexadecane membranes model2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Exploring the role of different drug transport routes in permeability screening.
AID7975Percent recovery of 100 ug/mL compound after administration in cirrhotic patients2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
Studies on intestinal permeability of cirrhotic patients by analysis lactulose and mannitol in urine with HPLC/RID/MS.
AID1850982Displacement of thiazole orange from human telomeric 1ELN i-motif DNA at 10 equiv. at pH 5.5 by fluorescent intercalator displacement assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Identification of sugar-containing natural products that interact with i-motif DNA.
AID29845Estimation of fraction absorbed (Fa) in the human intestine using biosensor technology.2000Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11
SPR biosensor studies of the direct interaction between 27 drugs and a liposome surface: correlation with fraction absorbed in humans.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1850983Displacement of thiazole orange from human telomeric 1ELN i-motif DNA at 100 equiv. at pH 5.5 by fluorescent intercalator displacement assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Identification of sugar-containing natural products that interact with i-motif DNA.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID7588Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
Studies on intestinal permeability of cirrhotic patients by analysis lactulose and mannitol in urine with HPLC/RID/MS.
AID229573Ratio of lactulose and mannitol in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B)2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
Studies on intestinal permeability of cirrhotic patients by analysis lactulose and mannitol in urine with HPLC/RID/MS.
AID236268Fraction absorbed in human intestine after oral administration compound was measured2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Exploring the role of different drug transport routes in permeability screening.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1850976Binding affinity to human ILPR i-motif DNA assessed as change in melting temperature at 20 uM at pH 5.5 by FRET assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Identification of sugar-containing natural products that interact with i-motif DNA.
AID1850981Displacement of thiazole orange from human telomeric 1ELN i-motif DNA at 100 equiv. at pH 7.4 by fluorescent intercalator displacement assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Identification of sugar-containing natural products that interact with i-motif DNA.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID156204Binding to POPC/GMI liposomes using biosensor system2000Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11
SPR biosensor studies of the direct interaction between 27 drugs and a liposome surface: correlation with fraction absorbed in humans.
AID7977Percent recovery of 500 ug/mL compound after administration in cirrhotic patients2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
Studies on intestinal permeability of cirrhotic patients by analysis lactulose and mannitol in urine with HPLC/RID/MS.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1850979Displacement of thiazole orange from human telomeric IKF1 G4 quadruplex DNA at 100 equiv. at pH 7.4 by fluorescent intercalator displacement assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Identification of sugar-containing natural products that interact with i-motif DNA.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID28392Apparent permeability coefficient (Papp) (Caco-2 cell monolayer)2001Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12
Experimental and computational screening models for the prediction of intestinal drug absorption.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID29844Fraction absorbed after oral administration in humans2001Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12
Experimental and computational screening models for the prediction of intestinal drug absorption.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID236912Permeability Coefficient in 2/4/A1 cell model2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Exploring the role of different drug transport routes in permeability screening.
AID237585Tested for fraction of oral dose absorbed orally in humans2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
AID1850975Binding affinity to human ILPR i-motif DNA assessed as change in melting temperature at 20 uM at pH 7.4 by FRET assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Identification of sugar-containing natural products that interact with i-motif DNA.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,222)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990469 (21.11)18.7374
1990's480 (21.60)18.2507
2000's421 (18.95)29.6817
2010's628 (28.26)24.3611
2020's224 (10.08)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 93.71

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index93.71 (24.57)
Research Supply Index3.47 (2.92)
Research Growth Index4.89 (4.65)
Search Engine Demand Index226.32 (26.88)
Search Engine Supply Index2.76 (0.95)

This Compound (93.71)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials461 (19.53%)5.53%
Reviews2 (6.45%)6.00%
Reviews234 (9.91%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies107 (4.53%)4.05%
Observational0 (0.00%)0.25%
Observational19 (0.80%)0.25%
Other29 (93.55%)84.16%
Other1,540 (65.23%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (106)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Therapeutic Efficacy of Oral PEG3350 Plus Lactulose Versus Lactulose Alone in Patients of Acute on Chronic Liver Failure With Overt Hepatic Encephalopathy: A Single Blind Prospective Randomized Controlled Study [NCT03987893]Phase 460 participants (Anticipated)Interventional2018-05-20Recruiting
Phase II Double Blind Placebo-controled Randomized Comparative Multicentered Study of Efficacy and Safety of Lactofiltrum, Orally Administered Tablets (Produced by AVVA RUS, JSC) to Treat Atopic Dermatitis in Adults [NCT01124318]Phase 2/Phase 390 participants (Anticipated)Interventional2010-05-31Completed
Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis: An Open Label, Randomized Controlled Trial of Lactulose, Probiotics and No-therapy [NCT01178372]Phase 40 participants Interventional2008-09-30Recruiting
Pilot Study of the Effect of Lactulose on Post Caesarean Section Constipation [NCT01295138]30 participants (Anticipated)Interventional2011-02-28Not yet recruiting
A Prospective, Longitudinal Study to Investigate the Effect of Thermal Injury on Intestinal Permeability and Systemic Inflammation (HESTIA) [NCT03242434]Phase 118 participants (Actual)Interventional2018-01-29Terminated(stopped due to This trial was supporting the development of an asset which was terminated, thus the data from the study were no longer required.)
Primary Prophylaxis of Hepatic Encephalopathy in Patients With Cirrhosis: an Open Labeled Randomized Controlled Trial of Lactulose Versus no Lactulose [NCT01175538]Phase 40 participants Interventional2008-01-31Recruiting
A Single Center, Open-Label, Pilot Study to Determine the Safety, Efficacy, and Patient Preference of Kristalose as a Bowel Evacuant Prior to Colonoscopy [NCT01256541]Phase 120 participants (Anticipated)Interventional2010-12-31Completed
Blood Glucose Response After Oral Intake of Lactulose (Laevolac®) in Mildly Constipated Patients With Diabetes Mellitus Type 2 [NCT03666546]Phase 424 participants (Actual)Interventional2018-11-26Completed
A Randomized Controlled Trial Comparing Nifuroxazide Plus Lactulose With Lactulose Alone in the Treatment of Hepatic Encephalopathy in Egyptian Patients With Liver Cirrhosis [NCT05754996]Phase 3102 participants (Anticipated)Interventional2023-03-12Recruiting
Orocecal Transit Time and Fermentation in IBS [NCT03141268]1,000 participants (Anticipated)Observational2017-01-01Recruiting
Improved Bowel Cleansing Method for Colonoscopy Based on High Risk Population of Bowel Preparation#a Single-center,Endoscopist-blinded Randomized Controlled Trial [NCT05498714]150 participants (Anticipated)Interventional2022-07-18Recruiting
Efficacy and Safety of PEG 3350 for Treatment of Chronic Constipation [NCT03957668]Phase 3184 participants (Anticipated)Interventional2019-12-07Active, not recruiting
Efficacy and Safety of Linaclotide in Patients With Overlap of Functional Dyspepsia and Constipation-predominant Irritable Bowel Syndrome [NCT05134584]Phase 478 participants (Anticipated)Interventional2021-01-01Recruiting
A Randomized, Double-blind, Controlled Trial Comparing Nitazoxanide Plus Lactulose With Lactulose Alone Treatment of Overt Hepatic Encephalopathy [NCT02464124]Phase 2/Phase 3120 participants (Anticipated)Interventional2016-01-31Recruiting
Multicenter Study Evaluating the Efficacy of Dicopeg Junior in Comparison With Lactulose for the Treatment of Functional Constipation in Children Aged 6 Months to 6 Years. A Prospective, Randomized Study. [NCT03177434]Phase 4102 participants (Anticipated)Interventional2016-02-29Recruiting
Elucidating the Influence of Lactulose Intake on the Gut Microbiota Composition [NCT02397512]32 participants (Actual)Interventional2015-02-28Completed
Effect of Genetic Variation in Starch-digesting Enzymes on Digestibility and Glycemic Index of Rice Prepared in Different Ways [NCT03667963]40 participants (Actual)Interventional2018-08-29Completed
Efficacy of Lactulose Plus Intravenous Branched Chain Amino Acids Versus Lactulose Alone in Patients of Acute on Chronic Liver Failure With Overt Hepatic Encephalopathy: A Prospective Randomized Clinical Trial [NCT04238416]Phase 170 participants (Actual)Interventional2019-11-01Completed
Comparison of Three Different Schemes:Lactulose, L-ornithine L-aspartate, or Rifaximin, Versus Placebo, as Primary Prophylaxis of the Development of Hepatic Encephalopathy After Acute Variceal Bleeding in Cirrhotic Patients [NCT02158182]Phase 488 participants (Actual)Interventional2014-07-31Completed
A Multicenter, Single-Arm, Interventional, Phase 4 Study to Evaluate the Efficacy and Safety of Prucalopride in Combination With PEG or Lactulose in Women With Chronic Constipation (CC) [NCT02228616]Phase 4280 participants (Actual)Interventional2014-10-14Completed
Rifaximin Plus Lactulose Versus Lactulose Alone for the Treatment of Hepatic Encephalopathy: a Double Blind Randomized Trial [NCT01218568]120 participants (Actual)Interventional2010-10-31Completed
Method of Assessment of Driving Ability in Patients Suffering From Wakefulness Pathologies. Impact of Lactulose and Carnitine Treatment. [NCT01231828]55 participants (Actual)Interventional2009-09-30Completed
A Randomized Open Labelled Placebo Controlled Trial to Study the Efficacy of Bromocriptine in Patients With Hepatic/Cirrhosis Related Parkinsonism [NCT02265484]50 participants (Actual)Interventional2013-11-30Completed
A Trial to Improve Quality of Life in People With Cirrhosis - the Michigan Kristalose Trial [NCT05061992]Phase 2/Phase 356 participants (Actual)Interventional2021-11-10Completed
Efficacy of Polyethylene Glycol vs Lactulose With Isabgol in Acute Fissure-in-Ano: A Randomized Control Trial (PEGASIS Trial) [NCT05341180]Phase 2/Phase 3144 participants (Actual)Interventional2022-05-27Completed
Effect of Lactulose and/ or Polyethylene Glycol Solution for Bowel Preparation in Colonscopy: a Multi-center Prospective Randomized Study [NCT05076799]Phase 3200 participants (Actual)Interventional2021-09-01Completed
A Preference Study Comparing Kristalose® and Liquid Lactulose in the Treatment of Constipation [NCT00712543]Phase 450 participants (Actual)Interventional2009-06-30Completed
Comparison of Chinese Herbal Formula and Lactulose for Adults With Chronic Constipation-a Randomized ,Double-Blind, Controlled Trial [NCT00745147]Phase 393 participants (Actual)Interventional2008-07-31Completed
A Phase-I, Two-Stage, Double-Blind, Placebo-Controlled, Pharmacokinetic and Pharmacodynamic Trial of Low Doses of Intravenous 6β-Naltrexol (AIKO-150) in Opioid-Dependent Subjects. [NCT00829777]Phase 18 participants (Anticipated)Interventional2009-03-31Completed
Anal Dilatation for Infants and Children With Constipation [NCT02255747]100 participants (Anticipated)Interventional2014-09-30Recruiting
A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Progressive Renal Failure [NCT00748904]Phase 40 participants (Actual)Interventional2008-06-30Withdrawn
A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Renal Failure [NCT02086825]Phase 30 participants (Actual)Interventional2015-10-31Withdrawn
Assesment of Lactulose vs Lactobacillus Acidophilus Effect in CKD Patients [NCT05934552]150 participants (Anticipated)Observational2023-12-31Not yet recruiting
Probiotic E.Coli Nissle 1917 Comparing to Lactulose and Rifaximin in Patients With Mild (Stage 1-2) or Minimal Hepatic Encephalopathy [NCT04787276]42 participants (Actual)Interventional2017-01-10Completed
A Randomized, Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect of Increasing Intake Amounts of Two Novel Glycans on the Gut Microbiota of Healthy Subjects [NCT04619875]36 participants (Actual)Interventional2017-09-11Completed
Gut Permeability in Very Low Birth Weight Infants [NCT01756040]Phase 1211 participants (Actual)Interventional2013-02-01Completed
Bacterial Overgrowth Associated With Chronic Multisymptom Illness Complex [NCT00956150]Phase 1210 participants (Anticipated)Interventional2009-04-30Recruiting
Secondary Prophylaxis of Overt Hepatic Encephalopathy in Cirrhosis: a Randomized Controlled Trial of Colistin Versus Lactulose [NCT05279586]Early Phase 1316 participants (Anticipated)Interventional2022-03-31Not yet recruiting
Breath and Blood Ammonia Response to an Oral Protein Challenge [NCT02650245]12 participants (Actual)Interventional2015-10-31Completed
A Clinical Standardization Study of the Preferred Acupuncture Treatment Protocol to Treat Functional Constipation [NCT00508482]Phase 2475 participants (Actual)Interventional2008-04-30Completed
RICE Trial: Rifaximin In Chronic Hepatic Encephalopathy - A Randomized, Controlled Trial [NCT00364689]Phase 313 participants (Actual)Interventional2006-08-31Terminated(stopped due to Difficult to recruit participants)
Investigations of the Endocrine Colon in Healthy Individuals [NCT04159181]10 participants (Anticipated)Interventional2018-07-16Active, not recruiting
Performance of 13C Mannitol for in Vivo Measurement of Small Intestinal Permeability [NCT02603822]Phase 125 participants (Actual)Interventional2015-08-31Completed
An Exploratory Assessment of Small Bowel Transit Time and Small Bowel Bacterial Overgrowth Using the SmartPill Capsule [NCT00577772]17 participants (Actual)Interventional2007-11-30Terminated(stopped due to Enrollment Goal Not Met)
Prevention of Hepatic Encephalopathy by Administration of Rifaximin and Lactulose in Patients With Liver Cirrhosis Undergoing TIPS Placement: a Multi-centre Randomized, Double Blind, Placebo Controlled Trial. [NCT04073290]Phase 4238 participants (Anticipated)Interventional2020-01-21Recruiting
Efficacy of Combined Oral L-ornithine-L-aspartate and Oral Lactulose in Patients With Hepatic Encephalopathy [NCT00740142]Phase 435 participants (Actual)Interventional2008-09-30Completed
Improved Bowel Preparation Method for Colonoscopy Based on Different Risk Stratification:a Multicenter, Endoscopist-blinded Randomized Controlled Trial [NCT04582942]2,028 participants (Actual)Interventional2020-08-06Completed
The Effects of Lactulose Supplementation to Enteral Feedings in Premature Infants - A Pilot Study [NCT00616876]Phase 228 participants (Actual)Interventional2005-02-28Completed
Is Continuous Lactulose Therapy Necessary for Patients With Hepatic Encephalopathy? A Prospective Study of Controlled Lactulose Withdrawal [NCT00914056]7 participants (Actual)Interventional2008-09-30Completed
Does Small Intestinal Bacterial Overgrowth Contribute to Functional Dyspepsia [NCT00956397]55 participants (Actual)Interventional2007-08-31Completed
Effect of Polyethylene Glycol Versus Lactulose on Hepatic Encephalopathy in Patients With Liver Cirrhosis; a Randomized Clinical Trial (PEGHE Trial) [NCT04436601]Phase 4102 participants (Anticipated)Interventional2020-03-09Recruiting
The Role of Breath Testing in Enriching the Likelihood of Response to Rifaximin in Patients With Diarrhea IBS [NCT03729271]Phase 4110 participants (Anticipated)Interventional2020-01-09Recruiting
Improvement of Cognitive Function and Healthcare -Related Quality of Life After Lactulose Treatment in Children With Chronic Liver Disease [NCT00811434]Phase 216 participants (Actual)Interventional2009-01-31Terminated(stopped due to funding period ended)
Health Related Quality of Life in Patient With Chronic Liver Disease and Effect of Probiotics in the Treatment of MHE and Health Related Quality of Life [NCT01008293]Phase 2/Phase 3120 participants (Actual)Interventional2009-10-31Completed
A Randomized Unblinded Feasibility Study Evaluating the Use of Oral Administration of MB-102 Versus Dual Sugar Testing for Gut Permeability in Normal Subjects and Subjects With Active Small Bowel Crohn's Disease [NCT03962998]Early Phase 122 participants (Actual)Interventional2019-10-27Completed
Metformin's Effect on Glucagon-induced Endogenous Glucose Production, Protein Metabolism and Resting Energy Expenditure in Insulin Resistant Individuals. [NCT01956929]Phase 112 participants (Actual)Interventional2013-10-31Completed
Polyethylene Glycol Laxative (Macrogol 4000;Forlax®) for Treatment of Chronic Constipation in Children : A Phase III, Bicentric, Randomized, Double-blind, Lactulose Controlled Study. [NCT00255372]Phase 388 participants (Actual)Interventional2005-04-30Completed
Evaluate Lactulose for Bowel Preparation in Patients With Inflammatory Bowel Disease [NCT05878639]140 participants (Actual)Interventional2023-03-28Completed
Comparison Between Lactulose and Lactulose-Paraffin in Cirrhotic Patients: Impact on the Recurrence of Encephalopathy, Tolerance and Adherence to Treatment, Costs, and Quality of Life [NCT02017119]Phase 240 participants (Actual)Interventional2011-01-31Completed
Efficacy and Accuracy of a New Diagnostic Scoring System to Differentiate Hirschsprung Disease From Hirschsprung Disease Allied Disorders in the Patients With Suspected Intestinal Dysganglinosis: a Prospective Study [NCT02216994]80 participants (Anticipated)Interventional2013-01-31Recruiting
LiveSMART: A Sequential, Multiple Assignment Randomized Trial to Prevent Falls in Patients With Cirrhosis [NCT05794555]Phase 3215 participants (Anticipated)Interventional2023-06-13Recruiting
Efficacy of Topiramate in Patients Wih Migraine-Associated Dizziness [NCT00732108]0 participants (Actual)Interventional2008-11-30Withdrawn(stopped due to No subjects enrolled)
A Single Center, Randomized, Single-blind Pilot Study to Determine the Safety, Efficacy, and Patient Preference of Split-Dose Regimen of Crystalline Lactulose for Cleansing of the Colon as a Preparation for Colonoscopy in Adults [NCT01650870]Phase 240 participants (Actual)Interventional2012-07-31Completed
Randomized Controlled Trial Evaluating the Efficacy of Polyethylene Glycol 3350-electrolyte Solution (GoLYTELY®) in Patients With Hepatic Encephalopathy. [NCT01283152]50 participants (Actual)Interventional2011-01-31Completed
Validation of the Small Intestine Microbiome Aspiration (SIMBA) Capsule [NCT04094558]30 participants (Actual)Interventional2021-10-27Completed
Serum Endotoxins, Inflammatory Mediators and MR Spectroscopy Before and After Treatment in Minimal Hepatic Encephalopathy [NCT01446523]60 participants (Actual)Interventional2011-10-31Completed
Hepatic Encephalopathy: Lactulose or Polyethylene Glycol (H.E.L.P.) [NCT01923376]0 participants (Actual)Interventional2013-02-28Withdrawn(stopped due to Not enough staff to collect data)
Lactulose for the Prevention of Nosocomial Infections in Children [NCT00273949]100 participants Interventional2006-01-31Active, not recruiting
A Single Centre Study to Assess the Safety and Efficacy of Movicol in the Treatment of Faecal Impaction in Children Followed by a Double Blind, Randomised Phase to Compare the Safety and Efficacy of Movicol and Lactulose for Maintenance Therapy [NCT00404040]Phase 260 participants Interventional2000-10-31Completed
An Open, Randomized, Parallel Group, Single Center Study to Investigate the Effect of Lactulose Versus Plantago Ovate on the Quality of Life of Patients With Hard Stools and Hemorrhoids or Anal Fissure [NCT00160290]Phase 497 participants (Actual)Interventional2002-03-31Terminated(stopped due to This trial discontinued on 30 JUN 2006 due to a lack of enrolment)
Lactulose vs. Polyethylene Glycol as Bowel Preparation for Colonoscopy in Adults [NCT05726344]150 participants (Actual)Interventional2023-02-10Completed
Randomized Double Blind Placebo Controlled Trial of Lactulose for the Prevention of Hepatic Encephalopathy in Cirrhotic Patients With Upper Gastrointestinal Hemorrhage [NCT00553423]Phase 3128 participants (Anticipated)Interventional2007-11-30Recruiting
Lubiprostone for the Treatment of Functional Constipation in the Under 18 Years Patients: A Randomized, Controlled Trial. [NCT05144295]Phase 3274 participants (Actual)Interventional2022-01-01Completed
Blood Glucose Response After Oral Intake of Lactulose in Healthy Volunteers [NCT02968498]24 participants (Actual)Interventional2016-11-30Completed
Oro-cecal Transit Time in Healthy Indian Subjects Using Scintigraphy and Its Correlation With Lactulose Hydrogen Breath Test- A Pilot Study [NCT05004207]50 participants (Anticipated)Observational2021-07-01Recruiting
A Single Centre Study to Assess the Safety and Efficacy of Movicol in the Treatment of Faecal Impaction in Children Followed by a Double Blind, Randomised Phase to Compare the Safety and Efficacy of Movicol and Lactulose for Maintenance Therapy [NCT00403858]Phase 260 participants Interventional2000-10-31Completed
A Randomized, Double-Blind, Multicenter, Parallel Pilot Clinical Trial to Study the Efficay of a Treatment of Lactulose + Vitamin D + Calcium 0.5 g Concurrently Controlled With a Standard Treatment (Vit D + Calcium) in Bone Mass Preservation Among Postmen [NCT00160264]Phase 440 participants Interventional2003-01-31Completed
An Observer-blinded, Dose-finding Study to Investigate the Safety, Efficacy, and Patient Preference of Lactulose for Oral Solution With Bisacodyl for Cleansing of the Colon as a Preparation for Colonoscopy in Adults [NCT02123017]Phase 232 participants (Actual)Interventional2014-04-30Completed
Randomized Trial Comparing The Efficacy of PEG (Polyethylene Glycol) Versus Lactulose For Treatment Of Overt Hepatic Encephalopathy [NCT03100513]Phase 4100 participants (Anticipated)Interventional2017-03-11Recruiting
Diagnosis of Covert/Minimal Hepatic Encephalopathy by Means of Continuous Reaction Time Measurement [NCT01773538]136 participants (Actual)Interventional2013-01-31Completed
HELP Trial: Efficacy of L-Ornithine L-Aspartate and Polyethylene Glycol in Cirrhotic Patients With Overt Hepatic Encephalopathy [NCT05920213]Phase 4360 participants (Anticipated)Interventional2023-10-31Not yet recruiting
Quality of Life and Nutritional Improvements in Cirrhotic Patients Following Hepatic Encephalopathy Using Rifaximin. [NCT01842113]Phase 44 participants (Actual)Interventional2013-04-30Terminated(stopped due to PI Initiated study - PI left facility)
[NCT00375375]Phase 480 participants Interventional2004-01-31Completed
Comparison of Different Treatment Regimens in Patients With Stage 1-2 Type C Hepatic Encephalopathy: AST-120 vs Lactulose [NCT00558038]Phase 240 participants (Actual)Interventional2007-09-30Completed
Development of Non-invasive Methods to Study Gut Microbiome - Nutrition - Host Interactions [NCT05949411]100 participants (Anticipated)Interventional2023-07-01Recruiting
Crosstalk Between Mucosal-Associated Invariant T Cells and the Gut Microbiota and Mucosa in the Development of Type 1 Diabetes in Children [NCT05054361]180 participants (Anticipated)Observational2022-01-01Recruiting
Intravenous Branched-chain Amino Acids for Overt Hepatic Encephalopathy in Patients With Acute on Chronic Liver Failure - A Multi-centric Double-blind Randomized Controlled Trial [NCT05700695]Phase 1246 participants (Anticipated)Interventional2023-01-17Recruiting
Oral Lactulose is Not Inferior to The Standard Bowel Preparation Regimen for Bowel Preparation Prior Colonoscopy [NCT04794049]800 participants (Anticipated)Interventional2021-05-01Not yet recruiting
Mode of Action of Ondansetron, a 5-HT Receptor 3 Antagonist, in Lactulose Induced Diarrhoea [NCT03833999]Phase 416 participants (Actual)Interventional2018-10-16Completed
Investigating the Effects of Iron on the Gastrointestinal Tract in Health. [NCT04705662]48 participants (Actual)Interventional2021-03-01Completed
To Compare Efficacy and Safety of Lactulose Versus Polyethylene Glycol for Treatment of Overt Hepatic Encephalopathy in Cirrhotics: A Randomized Controlled Trial [NCT03448770]110 participants (Anticipated)Interventional2017-08-01Recruiting
A Multicenter, Randomized, Open-Label, Active-Controlled, Trial to Evaluate the Safety and Efficacy of Rifaximin 550 mg With and Without Lactulose in Subjects With a History of Recurrent Overt Hepatic Encephalopathy [NCT01842581]Phase 4222 participants (Actual)Interventional2013-01-08Completed
[NCT00004796]Phase 216 participants Interventional1994-11-30Completed
Biomarkers for Intestinal Permeability in Patients With Functional Lower Gastrointestinal Disorders Associated With Constipation. [NCT02246647]39 participants (Actual)Observational2014-09-30Completed
To Assess Efficacy of Nutritional Therapy in Secondary Prophylaxis of Hepatic Encephalopathy Versus Lactulose in Patients With Liver Cirrhosis- A Randomised Controlled Trial [NCT03161106]0 participants (Actual)Interventional2017-05-15Withdrawn(stopped due to due lack of funds)
Effectiveness Of Oral Lactulose Versus Lactulose Enema On The Time To Recovery From Overt Hepatic Encephalopathy [NCT05788627]Phase 4100 participants (Anticipated)Interventional2023-04-30Not yet recruiting
An Evaluation of the Efficacy and Safety of a Polyethylene Glycol (PEG) Based Bowel Protocol for the Management of Constipation in Peritoneal Dialysis Patients: A Pilot Study [NCT03148002]Phase 430 participants (Anticipated)Interventional2017-07-07Recruiting
High Volume Plasmapheresis for Refractory Hepatic Encephalopathy in Liver Intensive Care Unit-A Randomized Controlled Trial [NCT03115697]0 participants (Actual)Interventional2018-04-07Withdrawn(stopped due to lack of funds)
The Clinical Effects of Nitazoxanide in Hepatic Encephalopathy Patients: A Pilot Study [NCT02334163]Phase 236 participants (Anticipated)Interventional2014-12-31Recruiting
Alterations in the Intestinal Microbiome and Metabolic Profile of Patients With Cirrhosis Supplemented With Lactulose, Clostridium Butyricum, and Bifidobacterium Longum Infantis: a Randomized Placebo-controlled Trial [NCT05687409]Phase 4120 participants (Actual)Interventional2019-11-24Completed
Intestinal Permeability and Endometriosis [NCT03042923]46 participants (Actual)Observational2016-04-30Completed
A Phase 0 Platform Study Exploring the Use of Challenge Agents in Healthy Volunteers [NCT04821323]Early Phase 110 participants (Actual)Interventional2021-03-10Completed
Is Chronic Abdominal Pain in Pediatric Patients Due to Small Intestinal Bacterial Overgrowth? [NCT00619970]115 participants (Actual)Interventional2007-02-28Completed
[NCT02321371]73 participants (Actual)Interventional2014-10-19Completed
Professor of Tropical Medicine [NCT02520817]58 participants (Actual)Observational2013-01-31Completed
1L Oral Lactulose is an Effective Regimen for Bowel Preparation in Low-risk Patients [NCT05648318]255 participants (Actual)Interventional2022-01-08Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00508482 (10) [back to overview]Change of Mean Value of Abdominal Distention
NCT00508482 (10) [back to overview]Percentage of the Usage of Emergency Drugs
NCT00508482 (10) [back to overview]Percentage of the Usage of Emergency Drugs
NCT00508482 (10) [back to overview]Percentage of the Usage of Emergency Drugs
NCT00508482 (10) [back to overview]Change of Mean Value of Straining During Defecating
NCT00508482 (10) [back to overview]Change of Mean Value of Stool Consistency
NCT00508482 (10) [back to overview]Change of Mean Value of Incomplete Evacuation
NCT00508482 (10) [back to overview]Change of Mean Value of Cleveland Clinic Score
NCT00508482 (10) [back to overview]Change of Mean Weekly Spontaneous Bowel Movements
NCT00508482 (10) [back to overview]Time to the First Spontaneous Bowel Movement After the First Treatment
NCT00619970 (2) [back to overview]Number of Participants With SIBO at Baseline (Week 0) and at 2 Week Post Treatment
NCT00619970 (2) [back to overview]The Number of Participants at Baseline With SIBO
NCT00712543 (1) [back to overview]Patient Preference in Terms of Overall Preference and Preference of Taste, Consistency, and Portability.
NCT00811434 (1) [back to overview]Incidence of Minimal Hepatic Encephalopathy (MHE) in Children With Cirrhosis
NCT01283152 (3) [back to overview]Hospital Duration/Length of Stay
NCT01283152 (3) [back to overview]Number of Participants With an Improvement of 1 or More in HE Grade at 24 Hours
NCT01283152 (3) [back to overview]Change in HE Grade at 24 Hours
NCT01756040 (7) [back to overview]Stool Alpha-1 Antitrypsin
NCT01756040 (7) [back to overview]Percent Participants Exposed to Antibiotics Prior to La/Rh Measurement
NCT01756040 (7) [back to overview]Occurrence of Necrotizing Enterocolitis
NCT01756040 (7) [back to overview]Intestinal Permeability
NCT01756040 (7) [back to overview]Breastmilk Feeding Duration Prior to La/Rh Measurement
NCT01756040 (7) [back to overview]Stool Microbiota Relative Abundance
NCT01756040 (7) [back to overview]Postnatal Age Full Feeds Reached
NCT01842581 (6) [back to overview]Number of Participants Who Died Due to Any Reason
NCT01842581 (6) [back to overview]Number of Participants Reporting a First Breakthrough HE Episode
NCT01842581 (6) [back to overview]Number of Participants Who Were Hospitalized Due to HE Episode
NCT01842581 (6) [back to overview]Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
NCT01842581 (6) [back to overview]Change From Baseline in Critical Flicker Frequency (CFF) at Day 170
NCT01842581 (6) [back to overview]Change From Baseline in Total Chronic Liver Disease Questionnaire (CLDQ) Score at Day 170
NCT02123017 (4) [back to overview]Safety of Bisacodyl and Lactulose as a Bowel evacuant_AE Severity
NCT02123017 (4) [back to overview]Tolerability of and Preference for Bisacodyl and Lactulose as a Bowel Evacuant
NCT02123017 (4) [back to overview]Safety of Bisacodyl and Lactulose as a Bowel evacuant_AE Incidence
NCT02123017 (4) [back to overview]Efficacy of Bisacodyl and Lactulose as a Preparation for Colonoscopy.
NCT02246647 (14) [back to overview]Baseline Transmucosal Resistance (TMR) of Duodenal Mucosa
NCT02246647 (14) [back to overview]Cumulative E.Coli Bio- Particle K12 Concentration Across Colonic Mucosa
NCT02246647 (14) [back to overview]Cumulative E.Coli Bio- Particle K12 Concentration Across Duodenal Mucosa
NCT02246647 (14) [back to overview]Cumulative FITC-Dextran (4kDa) Concentration Across Colonic Mucosa
NCT02246647 (14) [back to overview]Cumulative FITC-Dextran (4kDa) Concentration Across Duodenal Mucosa
NCT02246647 (14) [back to overview]Duodenal Impedance
NCT02246647 (14) [back to overview]Lactose:C13 Mannitol Excretion Ratio 0-2hours
NCT02246647 (14) [back to overview]Mean Serum Endotoxin (Bacterial LPS) Levels
NCT02246647 (14) [back to overview]Rate of E.Coli Bio- Particle K12 Flux Across Colonic Mucosa
NCT02246647 (14) [back to overview]Rate of E.Coli Bio- Particle K12 Flux Across Duodenal Mucosa
NCT02246647 (14) [back to overview]Rate of FITC-Dextran (4kDa) Flux Across Colonic Mucosa
NCT02246647 (14) [back to overview]Rate of FITC-Dextran (4kDa) Flux Across Duodenal Mucosa
NCT02246647 (14) [back to overview]Baseline Transmucosal Resistance (TMR) of Colonic Mucosa
NCT02246647 (14) [back to overview]Lactulose:C13 Mannitol Excretion Ratio 8-24hrs.
NCT03242434 (3) [back to overview]Change From 0 to 5 Hours, and 0 to 24 Hours in the Ratio of Lactulose/Mannitol on Day 1
NCT03242434 (3) [back to overview]Change From 0 to 5 Hours, and 0 to 24 Hours in the Ratio of Lactulose/Mannitol Over Time for Thermal Injury Participants
NCT03242434 (3) [back to overview]Change From 0 to 5 Hours, and 0 to 24 Hours in the Ratio of Lactulose/Mannitol Over Time for Healthy Participants
NCT05061992 (6) [back to overview]Participants Who Fell
NCT05061992 (6) [back to overview]Daily Bowel Movements
NCT05061992 (6) [back to overview]Change in Overall Sleep Quality
NCT05061992 (6) [back to overview]Animal Naming Test (ANT)
NCT05061992 (6) [back to overview]Short Form-8 Health Survey (SF-8) at 28 Days
NCT05061992 (6) [back to overview]Regular Daily Activity Impairment

Change of Mean Value of Abdominal Distention

Score of abdominal distention was assessed every week according to patients' diaries during 4 weeks of treatment. Score ranges from '0' to '4'. '0' means none of symptoms and '4' means very severe symptoms. Change from baseline of the mean value of abdominal distention over 4 weeks of treatment was evaluated as the secondary outcome. The change was calculated as the value at baseline minus the average over 4 weeks of treatment. We corrected the mean value of abdominal distention by covariance because the data had significant difference among three groups at baseline. (NCT00508482)
Timeframe: over 4 weeks of treatment

Interventionunits on a scale (Mean)
Deep Needling Group0.762
Shallow Needling Group0.693
Lactulose Group0.661

[back to top]

Percentage of the Usage of Emergency Drugs

(NCT00508482)
Timeframe: over 4 weeks of treatment

Interventionpercentage of participants (Number)
Deep Needling Group9.65
Shallow Needling Group8.04
Lactulose Group33.91

[back to top]

Percentage of the Usage of Emergency Drugs

(NCT00508482)
Timeframe: at the 4th week of follow-up

Interventionpercentage of participants (Number)
Deep Needling Group10.53
Shallow Needling Group12.50
Lactulose Group30.43

[back to top]

Percentage of the Usage of Emergency Drugs

(NCT00508482)
Timeframe: at the 12th week of follow-up

Interventionpercentage of participants (Number)
Deep Needling Group17.11
Shallow Needling Group14.29
Lactulose Group29.57

[back to top]

Change of Mean Value of Straining During Defecating

Score of straining during defecating was assessed every week according to patients' diaries during 4 weeks of treatment. Score ranges from '0' to '4'. '0' means none of symptoms and '4' means very severe symptoms. Change from baseline of the mean value of straining during defecating over 4 weeks of treatment was evaluated as the secondary outcome. The change was calculated as the value at baseline minus the average over 4 weeks of treatment. We corrected the mean value of straining during defecating by covariance because the data had significant difference among three groups at baseline. (NCT00508482)
Timeframe: over 4 weeks of treatment

Interventionunits on a scale (Mean)
Deep Needling Group0.835
Shallow Needling Group0.789
Lactulose Group0.868

[back to top]

Change of Mean Value of Stool Consistency

Score of stool consistency was assessed every week according to patients' diaries during 4 weeks of treatment. Score ranges from '0' to '4'. '0' means none of symptoms and '4' means very severe symptoms. Change from baseline of the mean value of stool consistency over 4 weeks of treatment was evaluated as the secondary outcome. The change was calculated as the value at baseline minus the average over 4 weeks of treatment. We corrected the mean value of stool consistency by covariance because the data had significant difference among three groups at baseline. (NCT00508482)
Timeframe: over 4 weeks of treatment

Interventionunits on a scale (Mean)
Deep Needling Group0.414
Shallow Needling Group0.438
Lactulose Group0.701

[back to top]

Change of Mean Value of Incomplete Evacuation

Score of incomplete evacuation was assessed every week according to patients' diaries during 4 weeks of treatment. Score ranges from '0' to '4'. '0' means none of symptoms and '4' means very severe symptoms. Change from baseline of the mean value of incomplete evacuation over 4 weeks of treatment was evaluated as the secondary outcome. The change was calculated as the value at baseline minus the average over 4 weeks of treatment. (NCT00508482)
Timeframe: over 4 weeks of treatment

Interventionunits on a scale (Median)
Deep Needling Group0.75
Shallow Needling Group0.75
Lactulose Group0.75

[back to top]

Change of Mean Value of Cleveland Clinic Score

Cleveland Clinic Score was assessed by doctors which contains eight items about constipation-related symptoms. Score ranges from '0' to '30'. '0' means none of symptoms and '30' means very severe symptoms. The change was calculated as the value at baseline minus the average over 4 weeks of treatment. (NCT00508482)
Timeframe: over 4 weeks of treatment

Interventionunits on a scale (Median)
Deep Needling Group4.5
Shallow Needling Group4.38
Lactulose Group4

[back to top]

Change of Mean Weekly Spontaneous Bowel Movements

Spontaneous bowel movements per week were assessed every week during 4 weeks of treatment according to patients' diaries. Weekly spontaneous bowel movements were also assessed at the 4th and 12th week of follow-up according to patients' diaries. (NCT00508482)
Timeframe: over 4-week treatment, at the 4th week of follow-up, at the 12th week of follow-up

,,
Interventionstools/week (Median)
over 4 weeks of treatmentat the 4th week of follow-upat the 12th week of follow-up
Deep Needling Group222
Lactulose Group211
Shallow Needling Group221.5

[back to top]

Time to the First Spontaneous Bowel Movement After the First Treatment

(NCT00508482)
Timeframe: counting by hours

Interventionhours (Mean)
Deep Needling Group27.08
Shallow Needling Group36.68
Lactulose Group16.52

[back to top]

Number of Participants With SIBO at Baseline (Week 0) and at 2 Week Post Treatment

(NCT00619970)
Timeframe: baseline (week 0) and at 2 weeks post treatment

,
InterventionParticipants (Count of Participants)
At baseline2 weeks
Children Receiving Placebo2419
Children Receiving Rifaximin4437

[back to top]

The Number of Participants at Baseline With SIBO

(NCT00619970)
Timeframe: upon enrollment

InterventionParticipants (Count of Participants)
Healthy Control14
Children Receiving Rifaximin44
Children Receiving Placebo24

[back to top]

Patient Preference in Terms of Overall Preference and Preference of Taste, Consistency, and Portability.

(NCT00712543)
Timeframe: 14 days

,
Interventionparticipants (Number)
Preferred liquid lactulose overallPreferred powder lactulose overallNo preference overallPreferred liquid lactulose in terms of tastePreferred powder lactulose in terms of tasteNo preference in terms of tastePreferred liquid lactulose in terms of consistencyPreferred powder lactulose in terms of consistencyNo preference in terms of consistencyPreferred liquid lactulose in terms of portabilityPreferred powder lactulose in terms of portabilityNo preference in terms of portability
Liquid, Then Powder Lactulose6118911571174165
Powder, Then Liquid Lactulose7124712471151175

[back to top]

Incidence of Minimal Hepatic Encephalopathy (MHE) in Children With Cirrhosis

failure of one cognitive function test indicates presence of MHE (NCT00811434)
Timeframe: baseline

Interventionparticipant (Number)
All Randomized Participants6

[back to top]

Hospital Duration/Length of Stay

(NCT01283152)
Timeframe: From time of admission to time of discharge or death

Interventiondays (Mean)
Polyethylene Glycol 3350-electrolyte Solution (GoLYTELY®)4
Lactulose8

[back to top]

Number of Participants With an Improvement of 1 or More in HE Grade at 24 Hours

Hepatic Encephalopathy Scoring Algorithm (HESA) at the 24 hour time point of when the subject was recruited (HESA improvement by at least 1 grade). HESA ranges from 0 to 3, with higher numbers indicating a more severe grade of hepatic encephalopathy. Study will continue at every 24 hour time point until the subject achieves his or her baseline mental state and/or grade 0 based on the HESA (NCT01283152)
Timeframe: Baseline to 24 hours

Interventionparticipants (Number)
Polyethylene Glycol 3350-electrolyte Solution (GoLYTELY®)21
Lactulose13

[back to top]

Change in HE Grade at 24 Hours

Hepatic Encephalopathy Scoring Algorithm (HESA) at the 24 hour time point of when the subject was recruited. HESA ranges from 0 to 3, with higher numbers indicating a more severe grade of hepatic encephalopathy. Study will continue at every 24 hour time point until the subject achieves his or her baseline mental state and/or grade 0 based on the HESA (NCT01283152)
Timeframe: Baseline to 24 hours

,
Interventionparticipants (Number)
improvement of 1 HESA gradeimprovement of 2 HESA gradesimprovement of 3 HESA gradesNo HESA improvementHESA grade 0 at 24 hours
Lactulose931122
Polyethylene Glycol 3350-electrolyte Solution (GoLYTELY®)1091210

[back to top]

Stool Alpha-1 Antitrypsin

Stool alpha-1 antitrypsin concentrations (NCT01756040)
Timeframe: 7-10 days postnatal

Interventionµg/ml (Mean)
Low Intestinal Permeability (IP) Group359.5
High IP Group1285.3

[back to top]

Percent Participants Exposed to Antibiotics Prior to La/Rh Measurement

Percent of participants with antibiotic exposure prior to La/Rh measurement (NCT01756040)
Timeframe: 7-10 days postnatal

InterventionParticipants (Count of Participants)
Low Intestinal Permeability (IP) Group79
High IP Group67

[back to top]

Occurrence of Necrotizing Enterocolitis

Frequency of ≥ Stage 2 Necrotizing enterocolitis (NCT01756040)
Timeframe: 0-28 days postnatal

InterventionParticipants (Count of Participants)
Low Intestinal Permeability (IP) Group0
High IP Group0

[back to top]

Intestinal Permeability

Intestinal Permeability measured by urinary excretion of orally administered lactulose/rhamnose (La/Rh ratio) (NCT01756040)
Timeframe: 7-10 days postnatal

Interventionratio (Mean)
Gestational Age <29 wk0.0731
Gestational Age ≥29 Weeks0.0720

[back to top]

Breastmilk Feeding Duration Prior to La/Rh Measurement

Number of days breast milk feeding prior to La/Rh measurement between d7-10 days of age. (NCT01756040)
Timeframe: 7-10 days postnatal

Interventiondays (Mean)
Low Intestinal Permeability (IP) Group7.02
High IP Group6.1

[back to top]

Stool Microbiota Relative Abundance

Relative abundance (%) Clostridiales species (NCT01756040)
Timeframe: 7-10 days postnatal

Interventionpercentage of Clostridiales in stool (Median)
Low Intestinal Permeability (IP) Group6.52
High IP Group0.07

[back to top]

Postnatal Age Full Feeds Reached

Postnatal age when all nutrition is provided by enteral feeds (NCT01756040)
Timeframe: 0-100 days postnatal

Interventiondays (Mean)
Low Intestinal Permeability (IP) Group11.46
High IP Group22.02

[back to top]

Number of Participants Who Died Due to Any Reason

(NCT01842581)
Timeframe: From randomization (Day 1) up to end of study (Day 186)

InterventionParticipants (Count of Participants)
Rifaximin 550 mg BID2
Rifaximin 550 mg BID + Lactulose2

[back to top]

Number of Participants Reporting a First Breakthrough HE Episode

A breakthrough HE episode was defined as an increase of the Conn score to Grade greater than or equal to (≥) 2 (ie, 0 or 1 to ≥ 2). Conn score is widely used as a measure of mental state in HE. The scale used in Conn scoring system include: Grade 0=No personality or behavioral abnormality; Grade 1=Trivial lack of awareness, euphoria, or anxiety; shortened attention span, impairment of addition or subtraction; Grade 2=Lethargy, disorientation for time, obvious personality change, inappropriate behaviour; Grade 3=Somnolence to semi-stupor, responsive to stimuli, confused, gross disorientation, bizarre behaviour; Grade 4=Coma, unable to test mental state. The time to the first breakthrough HE episode was defined as the duration between the date of first dose of study drug and the date of first breakthrough HE episode. Number of participants reporting a first breakthrough HE episode during randomization to Month 6 is presented. (NCT01842581)
Timeframe: From randomization (Day 1) up to Day 170

InterventionParticipants (Count of Participants)
Rifaximin 550 mg BID28
Rifaximin 550 mg BID + Lactulose15

[back to top]

Number of Participants Who Were Hospitalized Due to HE Episode

An HE-related hospitalization was defined as a hospitalization directly resulting from HE, or when HE events occurred during hospitalization. The time to first HE-related hospitalization was defined as the duration between the date of first dose of study drug and the date of first HE-related hospitalization. Number of participants who were hospitalized due to HE episode during randomization to Month 6 is presented. (NCT01842581)
Timeframe: From randomization (Day 1) up to Day 170

InterventionParticipants (Count of Participants)
Rifaximin 550 mg BID23
Rifaximin 550 mg BID + Lactulose14

[back to top]

Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious AEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. TEAE was defined as an AE that occurred from first dose of study drug until last dose of study drug plus 5 days (for non-fatal AEs) or plus 30 days (for fatal AEs).A summary of non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section. (NCT01842581)
Timeframe: From randomization (Day 1) up to end of study (Day 186)

InterventionParticipants (Count of Participants)
Rifaximin 550 mg BID99
Rifaximin 550 mg BID + Lactulose81

[back to top]

Change From Baseline in Critical Flicker Frequency (CFF) at Day 170

The critical flicker frequency (CFF), a validated assessment of neurological function was assessed using a specialized CFF instrument. The CFF is the frequency at which the participant observes a constant light transition to a flickering light and was measured in Hertz. The CFF was measured on a continuous scale and was the mean of 8 separate fusion-to-flicker transition tests performed in rapid succession. Increases in CFF results represent improvement in neurological function in participants with HE. (NCT01842581)
Timeframe: Baseline, Day 170

,
Interventionhertz (Mean)
BaselineChange at Day 170
Rifaximin 550 mg BID35.141.09
Rifaximin 550 mg BID + Lactulose34.642.10

[back to top]

Change From Baseline in Total Chronic Liver Disease Questionnaire (CLDQ) Score at Day 170

CLDQ was used to measure health-related quality of life. CLDQ includes 29 items in the following 6 domains: abdominal symptoms (3 items), fatigue (5 items), systemic symptoms (5 items), activity (3 items), emotional function (8 items), and worry (5 items). All items were measured on a 7-point Likert scale, ranging from 0 to 6 with higher values indicating better quality of life. Each domain score of CLDQ was calculated as the mean of the responses of items in that domain. Overall CLDQ score was obtained by adding scores for each item and dividing by the total number of items. Overall CLDQ score ranged from 0 (most impairment) to 6 (least impairment) with higher scores indicating better quality of life. If at least half of the items were non-missing for a domain, mean values of the non-missing items for that domain were used as imputed values for missing values. If more than half of the items in a domain were missing, no values were imputed and domain score was considered as missing. (NCT01842581)
Timeframe: Baseline, Day 170

,
Interventionunits on a scale (Mean)
BaselineChange at Day 170
Rifaximin 550 mg BID4.130.29
Rifaximin 550 mg BID + Lactulose4.260.08

[back to top]

Safety of Bisacodyl and Lactulose as a Bowel evacuant_AE Severity

Safety determined by the severity of treatment emergent adverse events. (NCT02123017)
Timeframe: 1 day post last consumption

,,
InterventionPercentage of subjects (Number)
MildModerateSevere
135 Grams of Crystalline Lactulose2580
180 Grams of Crystalline Lactulose5000
90 Grams of Crystalline Lactulose0250

[back to top]

Tolerability of and Preference for Bisacodyl and Lactulose as a Bowel Evacuant

Tolerability assessed by a patient questionnaire. Overall tolerability as given by Visual Analog Scale (VAS): 100 represents maximally tolerable; 0 represents minimally tolerable (NCT02123017)
Timeframe: 1 day post last consumption

Interventionunits on a VAS scale (Mean)
90 Grams of Crystalline Lactulose65.4
135 Grams of Crystalline Lactulose68.5
180 Grams of Crystalline Lactulose71.3

[back to top]

Safety of Bisacodyl and Lactulose as a Bowel evacuant_AE Incidence

Safety determined by the incidence of treatment emergent adverse events. (NCT02123017)
Timeframe: 1 day post last consumption

Intervention% of patients with adverse events (Number)
90 Grams of Crystalline Lactulose25
135 Grams of Crystalline Lactulose33
180 Grams of Crystalline Lactulose50

[back to top]

Efficacy of Bisacodyl and Lactulose as a Preparation for Colonoscopy.

Efficacy assessed by the physician's determination of the cleanliness of the colon using the Boston Bowel Preparation Scale (BBPS). 9 is the maximum score, representing an fully cleansed colon; 0 is the minimal score, representing a colon with no cleaning. (NCT02123017)
Timeframe: 10-14 hours post last consumption

Interventionunits on a scale (Mean)
90 Grams of Crystalline Lactulose5.7
135 Grams of Crystalline Lactulose7.4
180 Grams of Crystalline Lactulose7.8

[back to top]

Baseline Transmucosal Resistance (TMR) of Duodenal Mucosa

(NCT02246647)
Timeframe: Baseline

InterventionΩ*sq.cm (Mean)
Healthy Volunteers29.8
IBS - C28.16

[back to top]

Cumulative E.Coli Bio- Particle K12 Concentration Across Colonic Mucosa

(NCT02246647)
Timeframe: 3 hours post E.coli Bio- Particle administration

InterventionCFU/ml (Mean)
Healthy Volunteers1.07*10^4
IBS - C2.09*10^4

[back to top]

Cumulative E.Coli Bio- Particle K12 Concentration Across Duodenal Mucosa

(NCT02246647)
Timeframe: 3 hours post E.coli Bio- Particle administration

InterventionCFU/ml (Mean)
Healthy Volunteers1.48*10^4
IBS - C1.82*10^4

[back to top]

Cumulative FITC-Dextran (4kDa) Concentration Across Colonic Mucosa

(NCT02246647)
Timeframe: 3 hours post FITC-Dextran (4kDa) administration

Interventionng/mL (Mean)
Healthy Volunteers132.2
IBS - C122.5

[back to top]

Cumulative FITC-Dextran (4kDa) Concentration Across Duodenal Mucosa

This is not a pharmacokinetic or pharmacodynamic measure. Hence only one time assessment is made 3 hours after FITC-Dextran (4kDa) administration. (NCT02246647)
Timeframe: 3 hours post FITC-Dextran (4kDa) administration

Interventionng/mL (Mean)
Healthy Volunteers123.3
IBS - C156.8

[back to top]

Duodenal Impedance

(NCT02246647)
Timeframe: Baseline

InterventionΩ (Mean)
Healthy Volunteers705.9
IBS - C729.5

[back to top]

Lactose:C13 Mannitol Excretion Ratio 0-2hours

(NCT02246647)
Timeframe: 0-2 hr post-test dose administration

InterventionRatio (Mean)
Healthy Volunteers0.007
IBS - C0.01

[back to top]

Mean Serum Endotoxin (Bacterial LPS) Levels

(NCT02246647)
Timeframe: Fasting, one time measurement after 8 hours

InterventionEU/mL (Mean)
Healthy Volunteers0.35
IBS - C0.36

[back to top]

Rate of E.Coli Bio- Particle K12 Flux Across Colonic Mucosa

(NCT02246647)
Timeframe: Over 3 hours post E.coli Bio- Particle administration

InterventionCFU/h/sq.cm (Mean)
Healthy Volunteers4.26*10^5
IBS - C7.67*10^5

[back to top]

Rate of E.Coli Bio- Particle K12 Flux Across Duodenal Mucosa

(NCT02246647)
Timeframe: Over 3 hours post E.coli Bio- Particle administration

InterventionCFU/h/sq.cm (Mean)
Healthy Volunteers5.42*10^5
IBS - C5.70*10^5

[back to top]

Rate of FITC-Dextran (4kDa) Flux Across Colonic Mucosa

(NCT02246647)
Timeframe: Over 3 hours post FITC-Dextran (4kDa) administration

Interventionng/hr/sq.cm (Mean)
Healthy Volunteers4931
IBS - C6069

[back to top]

Rate of FITC-Dextran (4kDa) Flux Across Duodenal Mucosa

This is not a pharmacokinetic or pharmacodynamic measure. Hence only one time assessment is made 3 hours after FITC-Dextran (4kDa) administration. (NCT02246647)
Timeframe: Over 3 hours post FITC-Dextran (4kDa) administration

Interventionng/hr/sq.cm (Mean)
Healthy Volunteers4980
IBS - C6528

[back to top]

Baseline Transmucosal Resistance (TMR) of Colonic Mucosa

(NCT02246647)
Timeframe: Baseline

InterventionΩ*sq.cm (Mean)
Healthy Volunteers17.60
IBS - C19.06

[back to top]

Lactulose:C13 Mannitol Excretion Ratio 8-24hrs.

In vivo measurement of intestinal permeability using 13C mannitol & lactulose was used. High performance liquid chromatography-tandem mass spectrometry was used to measure concentrations calculated using the overall urine volume excreted in each interval. Concentrations of 13C adjusted for the % of 13C in 12C mannitol (4.98% of 12C mannitol excreted was subtracted from 13C mannitol values; determined by analyzing replicate samples of control urine). All lactulose or 13C mannitol concentrations 8-24hr post-ingestion were used to determine colonic permeability. Lactulose to 13C mannitol excretion ratios, as a measure of dose of saccharide administered, were calculated. (NCT02246647)
Timeframe: 8-24 hr post test-dose administration

InterventionRatio (Mean)
Healthy Volunteers0.01
IBS - C0.02

[back to top]

Change From 0 to 5 Hours, and 0 to 24 Hours in the Ratio of Lactulose/Mannitol on Day 1

Urine samples were collected at indicated time-points to determine the impact of thermal injury on the magnitude of small intestine permeability following the injury. As, L/M does not get metabolized, it gets filtered in the kidney and excreted in the urine. The impact of injury in thermal injury participants was compared with healthy participants using L/M ratio in urine. (NCT03242434)
Timeframe: 0 to 5 hours and 0 to 24 hours on Day 1

,
InterventionRatio (Mean)
Day 1, 0 to 5 hoursDay 1, 0 to 24 hours
Healthy Participants0.00780.0093
Thermally Injured Participants0.04150.0296

[back to top]

Change From 0 to 5 Hours, and 0 to 24 Hours in the Ratio of Lactulose/Mannitol Over Time for Thermal Injury Participants

Urine samples were collected at indicated time-points to determine the impact of thermal injury on the magnitude of small intestine permeability following the injury. As, L/M does not get metabolized, it gets filtered in the kidney and excreted in the urine. Baseline value was considered as Day 1 for both the groups. Change from Baseline is equal to post-Baseline visit value minus Baseline value. (NCT03242434)
Timeframe: 0 to 5 hours on Days 3, 5, 7, 11, 13 and 0 to 24 hours on Days 3, 5, 7, 9, 11 and 13

InterventionRatio (Mean)
Day 3, (0-5 hours), n= 3Day 5, (0-5 hours), n= 3Day 7, (0-5 hours), n= 2Day 11, (0-5 hours), n= 1Day 13, (0-5 hours), n= 1Day 3, (0-24 hours), n= 3Day 5, (0-24 hours), n= 3Day 7, (0-24 hours), n= 2Day 9, (0-24 hours), n= 2Day 11, (0-24 hours), n= 2Day 13, (0-24 hours), n= 1
Thermally Injured Participants-0.0037-0.02130.0566-0.1044-0.00430.0111-0.00460.0178-0.0327-0.0218-0.0634

[back to top]

Change From 0 to 5 Hours, and 0 to 24 Hours in the Ratio of Lactulose/Mannitol Over Time for Healthy Participants

Urine samples were collected at indicated time-points to determine the impact of thermal injury on the magnitude of small intestine permeability following the injury. As, L/M does not get metabolized, it gets filtered in the kidney and excreted in the urine. Baseline value was considered as Day 1 for both the groups. Change from Baseline is equal to post-Baseline visit value minus Baseline value. (NCT03242434)
Timeframe: 0 to 5 hours and 0 to 24 hours on Day 8 and Day 15

InterventionRatio (Mean)
Day 8 (0-5 hours)Day 15 (0-5 hours)Day 8 (0-24 hours)Day 15 (0-24 hours)
Healthy Participants0.01320.00160.00920.0090

[back to top]

Participants Who Fell

Yes or no question on whether participant had experienced at least 1 fall in the past 28 days. (NCT05061992)
Timeframe: 28 days

InterventionParticipants (Count of Participants)
Lactulose1
No Treatment3

[back to top]

Daily Bowel Movements

Results show the percentage of days in a 28-day span in which participants experienced more than 5 daily bowel movements. All participants analyzed in each arm were included in calculating the results using the following formula: (days with >5 bowel movements) / (patient-days in study) The results are presented as a single number because they are a point estimate of a population level proportion (NCT05061992)
Timeframe: 28 days

Intervention% of participant-days with >5 bowels (Number)
Lactulose5
No Treatment2

[back to top]

Change in Overall Sleep Quality

Overall sleep quality was measured on a 5-point Likert scale, with a range of 1 (very bad sleep quality) to 5 (very good sleep quality). (NCT05061992)
Timeframe: Change between baseline (day 0) and 28 days

Interventionscore on a scale (Median)
Lactulose0.4
No Treatment0.0

[back to top]

Animal Naming Test (ANT)

Number of unique animals named within 1 minute by the participant. Values below show the change from baseline and the results from the test taken 28 days later. (NCT05061992)
Timeframe: 28 days

,
InterventionCount of Animals Named (Mean)
Change in ANTEnd of trial ANT
Lactulose3.721.2
No Treatment-0.1518.52

[back to top]

Short Form-8 Health Survey (SF-8) at 28 Days

The SF-8 is an abbreviated version of an original 36-item health survey (SF-36). It is a generic, multipurpose, quality of life instrument, containing psychometrically based physical and mental health summary measures. The eight domains are general health, physical functioning, role physical, bodily pain, vitality, social functioning, mental health, and role emotional. Scores from the domains are combined and range from 0 (lowest quality of living) to 100 (highest quality of living). (NCT05061992)
Timeframe: 28 days

,
Interventionscore on a scale (Mean)
Change in SF-8 from BaselineEnd of Trial SF-8
Lactulose8.170.9
No Treatment6.5563.84

[back to top]

Regular Daily Activity Impairment

Single-question survey given to participants at baseline and again 28 days later. Participants ranked their daily activity impairment on a Likert scale of 0 (no impairment) to 10 (complete impairment) (NCT05061992)
Timeframe: 28 days

Interventionscore on a scale (Mean)
Lactulose3.0
No Treatment4.8

[back to top]